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SUMMARY 
Background: Patients with dementia have a higher prevalence of leukoaraiosis and cerebral 
microbleeds, which may be associated with a higher risk for hemorrhagic complications with 
oral anticoagulant therapy (OAC) prescribed for atrial fibrillation (AF) and thrombolytic 
treatment of ischemic stroke (IS). 
Objective: We aimed to (1) summarize current knowledge about the management of IS in 
patients with preexisting dementia; (2) assess the risks and benefits of warfarin, antiplatelets, 
and no treatment in patients with dementia and AF; (3) analyse the characteristics of dementia 
patients that died from IS and compare them to those who died from other causes.  
Methods: In the first study, we reviewed literature on the management of IS. The second and 
third studies were observational longitudinal analyses of patients registered in the Swedish 
Dementia Registry. Information on treatment, comorbidities, death was obtained from Swedish 
nationwide health registers. In the second study, Cox proportional hazards models were used 
to calculate the risk for IS, intracranial hemorrhage (ICH), any-cause hemorrhage, and death. 
In the third study, characteristics of patients with dementia dying from IS were assessed.  
Results: In the reviewed literature, patients with dementia were less likely to receive 
intravenous thrombolysis (IV tPA), secondary stroke prevention, different diagnostic 
procedures, invasive interventions or be admitted on stroke units compared to patients without 
dementia. OAC with warfarin was associated with lower risk of IS and mortality in patients 
with dementia. There were no differences in ICH between the treatment with warfarin, 
antiplatelets or no treatment, with a higher risk for any-cause hemorrhage with warfarin 
compared to antiplatelets. There were no differences in the use of neuropsychiatric medications 
between the patients who died from IS and those dying from other causes. More than half of 
the patients that died from IS as shown in their death certificate had not been registered in the 
Swedish Stroke Register (Riksstroke) in the year before death. 
Conclusions: Patients with dementia are less likely to receive complex management of IS 
compared to patients without dementia. This study supports the use of warfarin in appropriate 
cases in patients with dementia. The low percentage of patients on warfarin treatment indicates 
that further gains in stroke prevention are possible. Concomitant treatment with 
neuropsychiatric medications for patients with dementia did not influence mortality. 
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POVZETEK 
Uvod: Bolniki z demenco imajo višjo prevalenco levkoaraioze in možganskih mikrokrvavitev, 
ki so lahko povezane z višjim tveganjem za hemoragične zaplete ob antikoagulantnem 
zdravljenju (AKZ) in trombolitičnem zdravljenju ishemične možganske kapi (IMK). 
Cilji: Preučiti, ali so bolniki z demenco, ki so zboleli z ishemično možgansko kapjo 
obravnavani drugače kot bolniki brez demence. Preučiti tveganje in učinkovitost AKZ z 
varfarinom za zdravljenje atrijske fibrilacije (AF) pri bolnikih z demenco. Preučiti značilnosti 
bolnikov z demenco, ki so umrli zaradi možganske kapi in jih primerjati z bolniki z drugimi 
vzroki smrti. 
Metode: V prvem delu je bil opravljen pregled literature o obravnavi bolnikov z demenco pri 
akutni IMK z uporabo podatkovne baze PubMed. V drugem in tretjem delu je bila izvedena 
longitudinalna kohortna študija, ki temelji na podatkih o bolnikih iz švedskega nacionalnega 
registra za demence (SveDem). V drugem delu smo primerjali osnovne značilnosti bolnikov z 
AKZ, z antiagregacijsko terapijo in tistimi brez antitrombotične terapije. Coxov regresijski 
model je bil uporabljen za oceno ogroženosti za IMK, znotrajmožgansko krvavitev (ZMK), 
krvavitev in smrt. V tretjem delu smo analizirali značilnosti bolnikov z demenco, ki so umrli 
zaradi IMK.  
Rezultati: V pregledani literaturi so bili bolniki z demenco ob akutni IMK manj pogosto 
zdravljeni z IV tPA, redkeje so prejeli sekundarno preventivo IMK, različne diagnostične 
preiskave, invazivne posege in bili redkeje sprejeti na enoto za možgansko kap kot bolniki brez 
demence. AKZ z varfarinom za zdravljenje AF pri bolnikih z demenco je bilo povezano z 
manjšim tveganjem za IMK in z manjšo umrljivostjo v primerjavi z bolniki brez terapije. 
Zdravljenje z varfarinom je bilo povezano z manjšim povečanjem tveganja za krvavitev v 
primerjavi z antiagregacijsko terapijo, vendar brez povečanega tveganja za ZMK. Bolniki, ki 
so umrli zaradi IMK in bolniki, ki so umrli zaradi drugih vzrokov, se med seboj niso razlikovali 
glede prejemanja nevropsihiatričnih zdravil. Več kot polovica bolnikov, pri katerih je bila IMK 
kot vzrok smrti, zabeležena na mrliškem listu, ni bila predhodno vpisanih v register za 
možganske kapi.  
Zaključki: Bolniki z demenco so ob akutni IMK redkeje deležni kompleksnih diagnostičnih 
preiskav in zdravljenja kot bolniki brez demence. Rezultati te raziskave podpirajo uporabo 
varfarina pri izbranih bolnikih z demenco. Nizek odstotek bolnikov z demenco, zdravljenih z 
14
varfarinom, kaže na možnost za izboljšave pri preventivi IMK. Zdravljenje z 
nevropsihiatričnimi zdravili ni bilo povezano z večjo umrljivostjo.  
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OUTLINE OF THE THESIS 
Introduction 
The remarkable increase in life expectancyduring the 20th century has led to concomitant 
global increase in the prevalence of cerebrovascular diseases and dementia.1, 2 According to the 
Global Burden of Disease data, in 2013 there were 6.7 million deaths from stroke (51% died 
from ischemic stroke (IS)) and almost 25.7 million stroke survivors (71% with IS).3 Globally, 
the proportional contribution of stroke to disability and death compared to all diseases 
increased between 1990-2013 from 10% to 12%. However, there was a diverging trend in 
stroke incidence between developed and developing countries. More than a 100% increase of 
stroke incidence was observed in developing countries, while in developed countries a 42% 
decrease was found.4 There are also indications of declining incidence of dementia in 
developed countries.5-7 This may be a consequence of better control of cardiovascular risk 
factors and better socioeconomic status during the last decades.7 On the other hand, the 
prevalence of IS nearly doubled from 1990 to 2013͕which can be attributed to an aging 
population. The number of stroke events in Europe in the next years is likely to increase from 
1.1 million per year in 2000 to more than 1.5 million per year in 2025.8 Nearly half of all strokes 
strike after the age of 70 and almost a quarter occur in patients aged 85 or older.9 The 
prevalence of stroke in patients over 85 is between 10% – 19% and the incidence varies from 
22 to 57/1000 person years in this population.10-12   
The prevalence of dementia increases exponentially with age, affecting 5% of the population 
aged over 65, and up to 50% by age 90.13, 14  Within the first 5 years of diagnosis, nursing home 
placement occurs in 10% of patients per year.15 The primary risk factor for institutionalization 
is disease severity, including the degree of cognitive and functional impairment.16 The 
prevalence of dementia in nursing home residents worldwide differs by location, nation and 
region with a median prevalence of 58%.17 
The most common cause of dementia is Alzheimer’s disease (AD) which accounts for about 
two thirds of dementia cases.18, 19 AD is a neurodegenerative disease characterized by the 
accumulation of amyloid plaques and neurofibrillary tangles in the brain. However, the 
mechanism, by which clinical dementia relates to the presence of amyloid plaques and 
neurofibrillary tangles still remains largely unclear and improved understanding of AD 
pathogenesis is needed.20 The second most common type of dementia is vascular dementia 
(VD).21 VD is characterized by the loss of cognitive functions caused by reduced blood flow 
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to the brain that may develop as a consequence of a single or multiple brain infarcts.22 The 
distinction between a primary neurodegenerative process and vascular pathology may be 
difficult. Most AD cases have contributing vascular lesions and most patients diagnosed as 
having VD have some amyloid depositions. Therefore, the combination of AD and VD called 
mixed dementia (MD) is common and was even proposed to be the most common cause of 
dementia, in particular in the oldest patients.23 However, there is still a lack of consensus on 
the diagnostic criteria for MD.24   
Stroke and dementia frequently coexist and their association is bi-directional. Patients with 
dementia are at an increased risk for stroke andpatients with stroke are at an elevated risk of 
dementia.25, 26 The proportion of dementia among patients presenting with stroke is estimated 
to be 10%, and increases to 30% with recurrent strokes.27-31  In 85-year old individuals, stroke 
is more common in those with more severe dementia.12 The odds ratio (OR) for stroke is 2.8 
(95% confidence intervals (CI) 1.3–6.1) among those with mild dementia, 3.5 (95% CI 1.8–
6.9) for moderate dementia, and 6.9 (95% CI 3.7–2.8) for severe dementia, compared to 
dementia-free individuals.12 Dementia type is associated with specific causes of death – 
cerebrovascular diseases (CVD) are a significantly more common cause of death in VD32, 33 
patients compared to AD patients (33.3% vs. 9.3%).33, 34 However, most of the previous studies 
focused exclusively on AD patients and less information exists on stroke as a cause of death in 
other dementia types. 
Multiple mechanisms underlie the association between stroke and dementia. Stroke can be the 
main cause of dementia, which is generally classified as VD, or it can precipitate the onset of 
AD.35, 36 This is supported by autopsy findings showing that fewer amyloid plaques and 
neurofibrillary tangles led to clinical AD in the presence of lacunar infarcts,37 suggesting that 
cerebrovascular lesions may lower the threshold for clinical manifestation of AD.38 On the 
other hand, cognitive impairment and dementia are associated with an increased risk of 
subsequent stroke.39-41 The mechanisms are not fully understood, but one explanation is that 
cognitive impairment might reflect silent cerebrovascular events and cerebral small vessel 
disease (CSVD), which eventually develop into stroke.37, 42-44  Cardiovascular risk factors such 
as high blood pressure, dyslipidemia or diabetes mellitus (DM) are risk factors for dementia as 
well as for stroke, and may represent a common substrate to both conditions.39, 45, 46 Atrial 
fibrillation (AF) is also a risk factor for dementia47 and causes about 20% of all IS.48  Its 
prevalence increases with age, appearing in 10% of those older than 80 years.49  
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CSVD is commonly caused by age and vascular risk factors, or is associated with cerebral 
amyloid angiopathy (CAA).50 CSVD is more frequent in patients with cognitive impairment 
and dementia than in the general population.50-53 On autopsy, CAA is found in up to 98% of 
patients with AD.54, 55 In the general population, CAA is present in over 10 % of individuals 
over 60 years and in more than 50% over 90 years.56, 57 The consequences of CSVD on the 
brain parenchyma can be ischemic, manifesting as silent cerebral infarcts or white matter 
hyperintensities; or hemorrhagic, presenting as hemorrhages or cerebral microbleeds 
(CMBs).58 The presence of CMBs is associated with an increase in intracranial hemorrhage 
(ICH) complications with the thrombolysis treatment59-61 and anticoagulation.62, 63 
Leukoaraiosis and CAA have also been associated with a higher risk for ICH with oral 
anticoagulant (OAC) therapy.64 Similar mechanisms may also explain the suggested increased 
rate of ICH for aspirin treatment in patients with AD. 65  
Adherence to medical treatment and life-style interventions may be more difficult in patients 
with dementia, leading further to an increased risk of stroke.66, 67 It is known that cardiovascular 
diseases often coexist in patients with dementia,68 and 70% of patients use cardiovascular 
medication,69 therefore medication compliance and lifestyle advice are an important issue. 
However, studies show increased compliance in people with severe dementia compared to 
those with moderate dementia.70 This could be explained by the fact that patients with severe 
dementia are more likely to live with others who take care of administering their medication. 
Therefore, those with significant cognitive impairment, who live alone, are most likely to be 
non-adherent.70  
It is also extremely common for patients with all forms of dementia to develop behavioural and 
psychological symptoms of dementia (BPSD) at some stage (up to 90% according to some 
studies).71 BPSD include depression, apathy, agitation, delusions, hallucinations, aggression 
and sleep disorders.72 These symptoms are associated with major adverse effects on daily 
function, quality of life, and early placement in a nursing home.72 Antipsychotic drugs, which 
are sometimes used for behavioural disturbances in patients with dementia, also increase the 
risk of stroke.73 74, 75 In some studies, the risk of death was about 1.2 to 1.6 times higher in 
patients with dementia compared to the control group.76, 77 Additionally, patients who were 
taking anxiolytic and hypnotic drugs presented with a significantly increased risk of mortality 
and higher prevalence of stroke (10% vs.7%; p ≤ 0.001).78  
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In the past decades, major advances in stroke prevention, treatment, rehabilitation and 
organization of stroke care have led to improved functional prognosis and decreased 
mortality.79, 80 Strategies addressing risk factors, including arterial hypertension, DM and 
smoking cessation, have resulted in a sizable reduction in coronary heart disease and stroke.81 
Organized inpatient stroke care including stroke unit admission and use of thrombolysis has 
been shown to reduce death and disability irrespective of age, stroke severity and subtype,82 
and is progressively being extended to older patients.79, 83, 84 However, it is not certain whether 
these benefits extend to patients with pre-existing dementia.85, 86 There is scarce knowledge on 
the optimal management of stroke in patients with dementia, as this group has been consistently 
excluded from interventional studies.87-90 91 Dementia is not mentioned in the American Heart 
Association /American Stroke Association (AHA/ASA) or Food and Drug Administration 
(FDA) exclusion criteria for intravenous thrombolysis (IV tPA).92 The recent AHA/ASA 
guidelines formanagement of acute ischemic stroke states that patients with preexisting 
dementia may benefit from IV tPA, but individual considerations such as life expectancy and 
premorbid level of function are important to determine.92 Most studies suggest that patients 
with dementia do not receive the same intensity of care for a number of conditions, including 
stroke, but it is not clear whether the dementia diagnosis dominates therapeutic decisions or 
whether it is the cognitive impairment, which hinders access to care.93-97  
AF is the most common cardiac arrhythmia in older populations and is known to be related to 
dementia through various pathways.47 First, it is a strong risk factor for IS, which can lead to 
dementia. Second, lower cardiac output in AF leads to chronic cerebral hypoperfusion, which 
could cause damage to nerve cells.98 Third, a noncausal explanation is shared etiology because 
of overlapping risk factors, such as hypertension, DM, and hypercholesterolemia.47 
OAC therapy with vitamin K antagonists (VKAs) and non-vitamin K antagonist oral 
anticoagulants (NOACs) is indicated for IS prevention in patients with AF. Traditionally, the 
VKAs, notably warfarin, have been the cornerstone for stroke prevention in patients with AF.99 
OAC with warfarin effectively reduces stroke risk by ≈ 60% compared to placebo.100 
Compared to antiplatelet therapy, warfarin is substantially more efficacious (by approximately 
40%).100, 101 The annual rate of major hemorrhage on antihothrombotic therapy does not differ 
significantly - 1.0% for the control group, 1.0% for the aspirin group, and 1.3% for the warfarin 
group.102 A meta-analysis of twenty-nine randomized controlled trials showed that the risk for 
ICH was doubled with an adjusted-dose warfarin compared with aspirin, although the absolute 
risk increase was small (0.2%/year).100 In each patient with AF, the benefits versus risks of 
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significantly - 1.0% for the control group, 1.0% for the aspirin group, and 1.3% for the warfarin 
group.102 A meta-analysis of twenty-nine randomized controlled trials showed that the risk for 
ICH was doubled with an adjusted-dose warfarin compared with aspirin, although the absolute 
risk increase was small (0.2%/year).100 In each patient with AF, the benefits versus risks of 
receiving OAC have to be considered. The CHA2DS2-VASc (Congestive heart failure, 
Hypertension, Age > 75, Diabetes, prior Stroke/transient ischemic attack, Vascular disease, 
Age 65-74 years, Sex category) score is recommended for stroke risk prediction in patients 
with AF to help select high risk patients, for which OAC treatment is indicated.103 To obtain 
the best stroke and bleeding prevention with warfarin, international normalized ratio (INR) has 
to be maintained between 2.0 and 3.0.104 This requires regular visits to primary care, daily 
compliance, periodic dose adjustments and awareness of food and drug interactions.  
With the recent introduction of NOACs, there is a promising alternative therapy – they are 
associated with significant reductions in IS (by 19% compared to warfarin), ICH, and mortality, 
and with similar major bleeding compared to warfarin, but with increased gastrointestinal 
bleeding.105 They also have fewer drug interactions and do not require frequent monitoring.105  
However, due to high costs of NOACs in relation to the quality of life gained, the cost-
effectiveness has been questioned.106 Additionally, studies on Swedish and Danish population 
have shown that the risks for IS or systemic embolism were similar with NOACs and warfarin 
treatment, which has been attributed to the high standard warfarin management in those 
countries.107, 108 In 2010, dabigatran was the first NOAC licensed for stroke prevention in AF109 
and since then NOACs have been increasingly used.110 In Sweden, the first NOAC dabigatran 
was available for stroke prevention in AF in 2011, rivaroxaban from 2012 and apixaban from 
2013 onward. European guidelines for treatment of AF now recommendNOACs before 
VKAs,111 while American guidelines on the prevention of stroke in nonvalvular AF 
recommend VKAs or NOACs.112  
OAC therapy may be underused or inconsistently prescribed in older patients with dementia.113 
Patients with dementia have often been excluded from studies establishing the benefit of 
warfarin and there are still few studies on stroke prevention and treatment in this population.64 
Old age and dementia are associated with a greater risk for hemorrhagic complications through 
different mechanisms, including falls and polypharmacy leading to interactions with warfarin 
metabolism. For these reasons, the American Academy of Neurology guidelines for stroke 
prevention in AF state that data in patients with AF who have moderate to severe dementia are 
insufficient to determine whether anticoagulants are safe.112 The European Stroke Organisation 
guidelines do not specifically contraindicate OAC in dementia patients, but do not recommend 
it in patients with co-morbid conditions such as falls or poor compliance.82 The European 
Society of Cardiology guidelines do not consider dementia to be a contraindication for 
anticoagulation unless compliance can be ensured.111  
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Objective 
1. The aim was to summarize current knowledge about the management of IS in patients with 
preexisting dementia in comparison to patients without dementia.  
2. To assess the risks and benefits of OAC with warfarin for the treatment of AF in patients 
with dementia and compare it with patients receiving antiplatelet treatment and patients with 
no antithrombotic treatment.  
3. To analyze the characteristics of dementia patients that died from IS and compare them to 
patients who died from other causes.  
 
Hypothesis 
1. Patients with preexisting dementia are managed differently for acute IS compared to the 
general population in the organizational aspects of stroke care (arrival time to the emergency 
department, access to diagnostics, access to stroke unit care), prevention of stroke 
(anticoagulation for patients with atrial fibrillation, antiplatelet treatment, use of statins), 
treatment of acute IS (IV tPA, endovascular treatment) and rehabilitation. 
2. Anticoagulant therapy for AF compared to antiplatelet treatment in patients with dementia 
is associated with a lower risk of IS and lower mortality, but with an increased risk of 
hemorrhage, which is relatively low compared to the benefit of IS prevention.  
3. Patients with an early phase dementia (Mini Mental State Examination (MMSE) > 20) 
treated for behavioural and psychological symptoms of dementia have a higher risk for death 
from IS.  
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METHODS 
 
The thesis consists of 3 papers.  
 
Paper 1 
For this review we identified studies through searches of PubMed with the search terms 
“dementia”, “elderly”, “age”, and “older” in combination with “stroke”, “cerebrovascular”, and 
“ischemia”. International stroke guidelines were used as an index, and every aspect of stroke 
care was researched in relationship to dementia with the relevant search terms in PubMed. 
Publications in English, Spanish, French, Slovenian or Swedish were subject to review. The 
final reference list was selected on the basis of relevance to the topics covered in this review.64 
 
Paper 2 
We performed a longitudinal cohort study on patients registered in the Swedish Dementia 
Registry (SveDem). Information on AF, treatment and comorbidities was obtained from the 
Swedish Patient Register and the Swedish Prescribed Drug Register. Data on death were 
obtained from the Swedish Population Register.  
 
Quality registries and study population 
SveDem was established in May 2007 with the aim to monitor the care of patients with 
dementia in Sweden.114 Patients with dementia are registered at the time of their dementia 
diagnosis by physicians in memory clinics or primary care units. Diagnoses are made according 
to the International Classification of Diseases 10 (ICD-10) criteria,115 with specific criteria used 
for the different dementia types. The following dementia disorders are included in SveDem: 
AD, VD, mixed AD and VD (MD), dementia with Lewy bodies (DLB), frontotemporal 
dementia (FTD), Parkinson's disease dementia (PDD), unspecified dementia (UD) and other 
dementia disorders (OD). For this study, the diagnoses were classified as AD, VD, MD or OD. 
Information on age, sex, MMSE score, use of medication and living conditions was obtained 
from SveDem at the time of dementia diagnosis. 
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Information about co-morbidities occurring from 1998 until the end of 2014, coded according 
to ICD-10116, was collected from the Swedish Patient Register. This register covers inpatient 
and outpatient specialist care visits in Sweden.117 Patients with AF were identified by the code 
I48, present either as main or contributory diagnosis at any time point between the year 1998 
and the date of dementia diagnosis. Other comorbidities identified as either main or 
contributory diagnosis from 1998 until the time of dementia diagnosis were DM (E10-E13), 
hypertension (I10-I15), liver diseases (K70-77), kidney diseases (N10-19), heart failure (I50), 
presence of cardiac pacemaker (Z950, DF016, DF014, FPE, FPF, FPG, FPJ, DZXG40 or 
ZXG50) and ischemic heart disease (I20-I25).118 
Furthermore, previous main diagnoses of stroke of any type (I64), IS (I63), nontraumatic ICH 
(I60-I62) and traumatic ICH (S063-S068) from 1998 until the time of dementia diagnosis were 
identified. A composite variable of main diagnoses of systemic and ICH, both traumatic and 
spontaneous was considered (any-cause hemorrhage). Any-cause hemorrhage included 
traumatic ICH (S063-S068); nontraumatic ICH (I60-I62); hemorrhage from respiratory 
passages (R04); anemia (D50 and D62); hemorrhage unspecified (R58); gastrointestinal 
bleeding (K92); and traumatic shock (T794). For outcomes we used a record of the disease 
occurring as main diagnosis after the date of dementia diagnosis: IS (ICD-10 I63), 
nontraumatic ICH (ICD-10 I60-I62), any-cause hemorrhage (described above) and death 
(obtained from the Swedish Death Register). 
Drug use from 2005 to 2014 was obtained from the Swedish Prescribed Drug Register, which 
includes all prescription-drugs dispensed to patients in any pharmacy in Sweden.119 For each 
individual a medication list at the date of measure was constructed according to the filled 
prescriptions registered in the Swedish Prescribed Drug Register during the three-month period 
preceding the date of dementia diagnosis. 
Drugs were coded according to the Anatomical Therapeutic Chemical classification system: 
acetylsalicylic acid (B01AC06, N02BA01, N02BA51), warfarin (B01AA03), and clopidogrel 
(B01AC04). Patients treated with NOACs were excluded because these treatments were 
uncommon in Sweden during the study period. The following groups of treatment were 
considered: 1) patients receiving only warfarin treatment at the time of dementia diagnosis 
(patients with coexisting antiplatelet treatment were excluded), 2) patients with only 
antiplatelet treatment (receiving only aspirin, only clopidogrel or combination of aspirin with 
clopidogrel) and 3) patients without any antiplatelet or anticoagulant treatment. Drug 
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individual a medication list at the date of measure was constructed according to the filled 
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Drugs were coded according to the Anatomical Therapeutic Chemical classification system: 
acetylsalicylic acid (B01AC06, N02BA01, N02BA51), warfarin (B01AA03), and clopidogrel 
(B01AC04). Patients treated with NOACs were excluded because these treatments were 
uncommon in Sweden during the study period. The following groups of treatment were 
considered: 1) patients receiving only warfarin treatment at the time of dementia diagnosis 
(patients with coexisting antiplatelet treatment were excluded), 2) patients with only 
antiplatelet treatment (receiving only aspirin, only clopidogrel or combination of aspirin with 
clopidogrel) and 3) patients without any antiplatelet or anticoagulant treatment. Drug 
prescription was decided by their physician and was not randomized. The number of habitual 
drugs taken at the time of dementia diagnosis was used as a proxy for comorbidity, calculated 
after excluding warfarin and antiplatelets.120, 121  
This study complies with the Declaration of Helsinki and was approved by the regional ethical 
review board in Stockholm, Sweden (dnr 2015/743-31/4). Patients were informed of 
registration in SveDem and could decline participation. Data were de-identified before the 
analysis. 
 
Statistical analyses 
From 49,792 patients, 8,485 (17%) had a diagnosis of AF. After the exclusion of patients who 
used both antiplatelets and warfarin or other kinds of anticoagulants, the final study sample of 
patients with dementia and AF was 8,096. The baseline characteristics of the patients at the 
time of dementia diagnosis and the outcomes during the follow-up were compared between the 
treatment groups using the chi-square test or independent samples t-test. Descriptives are 
shown as means ± standard deviation (SD), median and interquartile range (IQR) or frequency 
(number - n and percentage - %), where appropriate.  
Survival analyses to identify factors associated with risk for IS, ICH, any-cause hemorrhage 
and death were performed using Cox proportional hazards regression models to estimate hazard 
ratios (HR) with 95% confidence intervals (CI). The proportionality of hazards was checked 
using visual procedures. Models adjusted for age and sex were performed. Subjects with 
observation time <1 day were excluded (n=6). The final adjusted models were arrived at by 
testing any variables that presented baseline differences between the groups with p<0.25 in 
univariate comparisons and other variables previously shown to affect mortality in Swedish 
patients with dementia:121 variables were then kept in the survival models if they were 
significantly associated with the outcome and/or substantially improved the model. The final 
models were adjusted for age, sex, number of medication, MMSE, dementia type (AD vs. 
others), nursing home placement and previous diagnosis of diabetes, hypertension, heart 
failure, IS, any-cause hemorrhage, liver diseases and kidney diseases. Models were repeated 
for all four outcomes: IS, ICH, any-cause hemorrhage and death. Adjusted and unadjusted 
models for all four outcomes were repeated with stratification by sex, previous pacemaker, 
previous IS and previous any-cause hemorrhage. We performed post-hoc propensity score 
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adjusted models. These were obtained from multiple logistic regression including the variables 
age, sex, number of medication, MMSE, dementia type (AD vs. others), nursing home 
placement, previous diagnosis of diabetes, hypertension, heart failure, pacemaker, IS, any-
cause hemorrhage, anemia, gastrointestinal bleeding, hip fracture, liver diseases and kidney 
diseases. The interactions between the number of medications and liver or kidney diseases were 
tested. Two linear splines with a node at 79 years (sample median) were used for age, while 
MMSE and number of drugs were entered as linear variables. Comorbidities were entered as 
dichotomous variables as described above.  
Two tailed p<0.05 was considered to be statistically significant in all analytical procedures. 
Analyses were performed using the Statistical Package for the Social Sciences software version 
22 (IBM Corporation, Armonk, NY, USA) and STATA® version 12.1 (StataCorp, College 
Station, TX, USA).118 
 
Paper 3 
We conducted a retrospective analysis of prospectively collected data of patients registered in 
the SveDem. Information about the causes of death was acquired from the Swedish Death 
Register, about comorbidities from the Swedish Patient Register and about drugs from the 
Swedish Prescribed Drug Register.  
Patients and their relatives were informed of the entry into SveDem and could decline 
participation or have their data removed at any time. Data were de-identified before analysis.  
 
Quality registries and study population 
Information about SveDem has been described in the methods for the previous paper. For this 
study, the following dementia disorders were included: AD, VD, MD, DLB, FTD, PDD, UD, 
OD. In the present study, we used the data of patients that were registered between 2007 and 
2014.  
Data on death were obtained from death certificates collected in the Swedish Death Register 
until December 2014. IS was included as the cause of death if it was mentioned either as the 
main or contributory cause (ICD-10 code I63). All other causes of death were included in the 
variable “dead from other causes”. Riksstroke, the Swedish national stroke registry, covers all 
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the SveDem. Information about the causes of death was acquired from the Swedish Death 
Register, about comorbidities from the Swedish Patient Register and about drugs from the 
Swedish Prescribed Drug Register.  
Patients and their relatives were informed of the entry into SveDem and could decline 
participation or have their data removed at any time. Data were de-identified before analysis.  
 
Quality registries and study population 
Information about SveDem has been described in the methods for the previous paper. For this 
study, the following dementia disorders were included: AD, VD, MD, DLB, FTD, PDD, UD, 
OD. In the present study, we used the data of patients that were registered between 2007 and 
2014.  
Data on death were obtained from death certificates collected in the Swedish Death Register 
until December 2014. IS was included as the cause of death if it was mentioned either as the 
main or contributory cause (ICD-10 code I63). All other causes of death were included in the 
variable “dead from other causes”. Riksstroke, the Swedish national stroke registry, covers all 
Swedish hospitals involved in acute stroke with a coverage >90% for IS events.122, 123 It 
includes information on the quality of care during the acute phase, rehabilitation and secondary 
prevention of stroke. Data on stroke events occurring between 2007 and 2014 were included 
and used to ascertain stroke diagnoses. Deaths were attributed to stroke if the death certificate 
contained stroke as the cause of death and the patient had a stroke registered in Riksstroke 
within 1 year prior to death. The place of death was either hospital, nursing home or at home.124  
Data on comorbidities were obtained from the Swedish Patient Registry that covers all hospital 
and specialist care in Sweden.117 Main diagnosis and additional diagnoses are registered with 
ICD 10 codes. In the present study, we considered a comorbidity present if the code appeared 
at least once as the main or additional diagnosis from 1998 until the end of 2014. We used the 
following codes for comorbidities: DM (E10-E13), arterial hypertension (I10-I15), anemia 
(D50 and D62), liver diseases (K70-77), kidney diseases (N10-19), heart failure (I50), AF 
(I48), previous femur fracture (S72), previous stroke (I64, I63, I60-I62). 
Information on drug use was obtained from the Swedish Prescribed Drug Register, which 
contains information on all dispensed prescriptions since July 2005 at Swedish pharmacies for 
the entire Swedish population.119 In the present study we analyzed drugs dispensed at the time 
of dementia diagnoses and up to 3 years prior to this date, using the following codes: 
antidiabetic drugs (A10), antithrombotic agents (B01), diuretics (C03), beta blocking agents 
(C07), calcium-channel blockers (C08), agents acting on the renin-angiotensin system (C09), 
lipid-modifying agents (C10), antipsychotics (N05A), antidepressants (N06A), cholinesterase 
inhibitors (ChEIs) (N06DA), memantine (N06DX01), anxiolytics (N05B), hypnotics and 
sedatives (N05C). The use of sleeping aids was obtained from SveDem since ATC codes do 
not always reveal the intention of the prescription. We further considered the total number of 
medication at the time of dementia diagnosis as a proxy for overall co-morbidity.124  
This study complies with the Declaration of Helsinki and was approved by the regional ethical 
review board in Stockholm, Sweden (dnr 2015/743-31/4). 
 
Statistical analyses 
Data are described as means ± SD, median and IQR or frequency (number—n and 
percentage—%), where appropriate. Baseline characteristics of the patients at the time of 
dementia diagnosis were compared between the patients who died from IS and were registered 
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in Riksstroke, patients who died from IS without having been registered in Riksstroke and those 
who died from other causes using the chi-square test or independent samples t-test, as 
appropriate. Age was compared using ANOVA with the Welch test because of non-
homogenous variances and the total number of drugs using the Kruskal-Wallis test. Logistic 
regression was used to assess the association of the place of death (hospital, nursing home or 
at home) with IS in the death certificate and having a Riksstroke registration. The final models 
were adjusted for age, sex, number of medication, MMSE, dementia type, previous diagnosis 
of DM, hypertension, heart failure, AF, stroke, any-cause hemorrhage, anemia, gastrointestinal 
bleeding, hip fracture, liver diseases and kidney diseases. Adjusted ORs with 95% CIs are 
presented. 
Two-tailed p < 0.05 was considered statistically significant in all analytical procedures. Data 
were analyzed using the Statistical Package for the Social Sciences software version 22 (IBM 
Corporation, Armonk, NY, USA). 
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Povzetek 
10% bolnikov z ishemično možgansko kapjo ima znano demenco. Posledično se zdravstveni 
delavci vedno pogosteje soočajo z obravnavo bolnikov z demenco, ki utrpijo ishemično 
možgansko kap. Bolniki z znano demenco manj pogosto prejmejo intravensko trombolizo za 
zdravljenje ishemične možganske kapi (0,56–10% v primerjavi s 1–16% tromboliz v splošni 
populaciji), so manj pogosto sprejeti na enoto za možgansko kap ali so deležni drugih oblik 
podpornega zdravljenja. Tudi antikoagulantno zdravljenje za sekundarno preventivo 
možganske kapi je pri bolnikih z atrijsko fibrilacijo redkeje uvedeno, kljub temu da trenutne 
smernice demence specifično ne navajajo kot izključitveni kriterij. Raziskav v tej populaciji je 
malo in imajo nasprotujoče si rezultate. 3 opazovalne študije so preučevale varnost in 
učinkovitost zdravljenja ishemične možganske kapi z intravensko trombolizo pri bolnikih z 
demenco. V dveh večjih ni bilo ugotovljenih pomembnih razlik v tveganju za 
znotrajmožgansko krvavitev in umrljivost pri bolnikih z in brez demence. Tveganje za 
znotrajmožgansko krvavitev je bilo pri bolnikih z demenco 14–19%. Za to populacijo manjkajo 
študije o endovaskularnem zdravljenju ishemične možganske kapi. Pri bolnikih z demenco je 
manjša verjetnost odpusta v domačo oskrbo (19 vs. 41% pri bolnikih brez demence) in večja 
verjetnost invalidnosti (64 vs. 59%) ali smrti tekom hospitalizacije (22 vs. 11%). Namen 
preglednega članka je bil zbrati obstoječe podatke iz literature o obravnavi akutne ishemične 
možganske kapi pri bolnikih z znano demenco in jih primerjati s splošno populacijo. Pregled 
obravnave ishemične možganske kapi je zajemal tako organizacijski vidik, zdravljenje akutne 
ishemične možganske kapi z intravensko trombolizo, sprejem na enoto za možgansko kap, 
uporabo podpornega zdravljenja. Podatki, ki podpirajo uporabo antikoagulantnega zdravljenja 
za sekundarno preventivo ishemične možganske kapi pri bolnikih z atrijsko fibrilacijo in 
antiagregacijsko zdravljenje bodo predstavljeni, kot tudi uporaba rehabilitacije in kako ti 
dejavniki vplivajo na izide zdravljenja. Nazadnje bo predstavljen etični vidik, vrzeli v znanju 
in predlogi za prihodnje raziskave.  
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An estimated 10% of stroke patients have an
underlying dementia. As a consequence, health
professionals often face the challenge of managing
patients with dementia presenting with an acute
stroke. Patients with dementia are less likely to
receive thrombolysis (0.56–10% vs. 1–16% throm-
bolysis rates in the general population), be admitted
to a stroke unit or receive some types of care.
Anticoagulation for secondary stroke prevention is
sometimes withheld, despite dementia not being
listedasanexclusioncriterion incurrent guidelines.
Studies in this population are scarce, and results
have been contradictory. Three observational stud-
ies have examined intravenous thrombolysis for
treatment of acute ischaemic stroke in patients with
dementia. In the two largest matched case–control
studies, there were no significant differences
between patients with and without dementia in the
risks of intracerebral haemorrhage ormortality. The
risk of intracerebral haemorrhage ranged between
14% and 19% for patients with dementia. Studies of
other interventions for stroke are lacking for this
population. Patients with dementia are less likely to
be discharged home compared with controls (19%
vs. 41%) and more likely to be disabled (64% vs.
59%) or die during hospitalization (22% vs. 11%).
The aim of this review was to summarize current
knowledge about the management of ischaemic
stroke in patients with pre-existing dementia,
including organizational aspects of stroke care,
intravenous thrombolysis, access to stroke unit
care and use of supportive treatment. Evidence to
support anticoagulation for secondary prevention of
stroke in patients with atrial fibrillation and anti-
platelet therapy in nonembolic stroke will be dis-
cussed, as well as rehabilitation and how these
factors influence patient outcomes. Finally, ethical
issues, knowledge gaps and pathways for future
research will be considered.
Keywords: dementia, stroke, thrombolysis.
Introduction
The worldwide increase in life expectancy has
led to an increase in the prevalence of cere-
brovascular diseases and dementia [1]. This is
despite indications of declining incidence of
dementia and stroke in developed countries [2–
4]. Stroke and dementia frequently coexist, and
patients with dementia are at increased risk of
stroke [5]. Consequently, health professionals
frequently face the challenge of managing
patients with dementia presenting with an acute
stroke [6].
Previous studies have suggested that dementia
negatively affects both survival and functional
outcomes after stroke [7, 8]. However, little is
known about the optimal management of stroke
in patients with dementia, as this group has been
consistently excluded from interventional studies
[9–13]. Clinicians need to be cautious when extrap-
olating the results of clinical trials to groups of
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patients with dementia presenting with an acute
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Previous studies have suggested that dementia
negatively affects both survival and functional
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patients excluded from these studies [14, 15]. Two
principles can be considered: whether there is
evidence or reason to believe (i) that the effect of
an intervention will be different from that in the
previously tested group and (ii) that there will be a
different risk profile in the new group. In dementia
patients with stroke, these principles apply to a
varying degree depending on the intervention
(Fig. 1).
In the past two decades, major advances in stroke
prevention, treatment, rehabilitation and organi-
zation of stroke care have led to improved func-
tional prognosis and decreased mortality [16].
Organized inpatient stroke care has been shown
to reduce death and disability irrespective of age,
stroke severity and subtype [17], and these inter-
ventions are progressively being extended to older
patients [16, 18, 19]. However, it is not certain
whether these benefits extend to patients with pre-
existing dementia [20, 21]. Findings from most
studies suggest that patients with dementia do not
receive the same intensity of care for a number of
conditions, including stroke, but it is not clear
whether the dementia diagnosis dominates thera-
peutic decisions or whether it is the cognitive
impairment that hinders access to care [6, 22].
The aim of this review was to summarize current
knowledge about the management of acute ischae-
mic stroke (IS) in patients with pre-existing demen-
tia, including organizational aspects of stroke care,
use and safety profile of intravenous (IV) throm-
bolysis, access to stroke unit care and use of
supportive treatment. Evidence for secondary
stroke prevention and rehabilitation, and how
these factors impact patient outcomes, will also
be discussed. Lastly, we will identify knowledge
gaps and highlight pathways for future research.
Search strategy
Studies for this review were identified through
searches of PubMed with the search terms
Fig. 1 Theoretical framework for the extrapolation of stroke interventions to patients with dementia. ICH, intracranial
haemorrhage.
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‘dementia’, ‘elderly’, ‘age’ and ‘older’ in combination
with ‘stroke’, ‘cerebrovascular’ and ‘ischemia’. The
American [23] and European [24] stroke guidelines
were used as an index, and every aspect of stroke
care was investigated in relationship to dementia
using the relevant search terms in PubMed. The
breadth of the subject precluded a systematic
review. No language restrictions were applied. The
final reference list was selected on the basis of
relevance and shortened for space considerations.
Epidemiology
According to the Global Burden of Disease data in
2013, there were 6.7 million deaths from stroke
and almost 25.7 million stroke survivors [1]. Glob-
ally, the proportional contribution of stroke to
disability and death compared to all diseases
increased by 2% between 1990 and 2013. How-
ever, the age- and sex-standardized incidence rates
of stroke are decreasing in developed countries,
offsetting the ageing of the population in these
regions [4]. There was a diverging trend in inci-
dence rates in developed and developing countries
with a significant increase in the proportional
contribution of stroke in developing countries and
no change in developed countries [1]. Nearly half of
all strokes occur after the age of 70, with almost a
quarter in patients aged 85 years or older [25].
The prevalence of dementia increases exponen-
tially with age, affecting 5% of the population over
65, and up to 50% by 90 years of age [26], although
there are indications of declining incidence in
developed countries amongst the oldest old
(≥85 years) [2, 3]. Within the first 5 years of diag-
nosis, nursing home placement was required in
10% of patients per year, according to a US study
[27]. The primary risk factor for institutionalization
is disease severity, including the degree of cognitive
and functional impairment [27].
The proportion of dementia amongst patients pre-
senting with stroke is estimated to be 10% [28].
Stroke is more common as dementia advances;
compared to dementia-free subjects, stroke was
almost three times more likely in those with mild
dementia, rising to seven times more likely in those
with severe dementia [29, 30].
Pathophysiology
Multiple mechanisms underlie the association
between stroke and dementia [31]. Stroke can be
the main cause of dementia, which is generally
classified as vascular dementia, or it can precip-
itate the onset of Alzheimer’s disease (AD) [32]. The
latter is supported by postmortem findings that
fewer plaques and tangles led to clinical AD in the
presence of lacunar infarcts [32], suggesting that
cerebrovascular lesions may lower the threshold
for clinical manifestation of AD. On the other
hand, cognitive impairment and dementia are
associated with increased risk of subsequent
stroke [33, 34]. The mechanisms underlying this
increased risk are not fully understood, but one
possibility is that cognitive impairment might
reflect silent cerebrovascular events and cerebral
small vessel disease (CSVD), which are associated
with higher risk of stroke [30, 32, 35]. Cardiovas-
cular disorders such as high blood pressure,
dyslipidaemia or diabetes are risk factors for
dementia as well as for stroke and may represent
a common substrate to both conditions (Fig. 2)
[30, 33].
Cerebral small vessel disease is commonly related
to vascular risk factors and age, or is associated
with cerebral amyloid angiopathy (CAA), and is
more frequently observed in patients with cogni-
tive impairment than in the general population
[36, 37]. On autopsy, CAA is found in up to 98%
of patients with AD [38], and within the general
population is found in 10% of individuals over
60 years and 50% of those over 90 years of age
[39]. The consequences of CSVD on the brain
parenchyma can be ischaemic, manifesting as
silent cerebral infarcts or white matter changes,
or haemorrhagic, presenting as haemorrhages or
cerebral microbleeds (CMBs) [39]. The presence of
CMBs is associated with an increase in throm-
bolysis-related intracerebral haemorrhage [40,
41] and has limited the use of thrombolysis and
anticoagulation in patients with dementia. Fur-
thermore, there is a correlation between the
number of CMBs and amyloid b 42 levels in
cerebrospinal fluid in patients with dementia
[42].
The apolipoprotein (APOE) e4 allele is linked to
increased susceptibility to both stroke and demen-
tia [43–45]. The APOE e4 allele appears to acceler-
ate the process leading to CAA-related hae-
morrhagic stroke [46]. APOE e4 increases stroke
risk through its effects on low-density lipoprotein
(LDL) cholesterol [47], but also enhances the early
stages of carotid atherosclerosis independent of
serum levels of total and LDL cholesterol [48].
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Adherence to treatment and lifestyle interventions
may be more difficult in patients with dementia,
further leading to increased risk of stroke [49, 50].
Cardiovascular diseases often coexist in patients
with dementia [51], and 70% use cardiovascular
medication [52]. Studies show increased compli-
ance in patients with severe dementia compared to
those with moderate dementia [53], which is likely
to be due to caregivers taking over responsibility for
medication. Drugs used for treatment of dementia
and its behavioural symptoms can also impact
cardiovascular risk; antipsychotic drugs, which
are sometimes used for behavioural disturbances
in patients with dementia, may also increase the
risk of stroke [54], and the findings of an observa-
tional study suggest that treatment with cholines-
terase inhibitors reduces the risk of myocardial
infarction and death in patients with AD [55].
Management of acute ischaemic stroke
Organizational aspects and chain of care
Care systems for stroke rely on the appropriate and
speedy intervention of different actors in a sequen-
tial manner during the chain of care [23]. This
begins with public education about stroke symp-
toms, training and activation of emergency number
systems, appropriate stroke identification by
prehospital care providers and transfer to a desig-
nated stroke centre [23]. All these steps may have a
higher likelihood of failure in patients with cogni-
tive impairment; patients may be unable to call for
help or describe symptoms, and relatives and
prehospital care providers may be less confident
in identifying new symptoms in the context of pre-
existing neurological impairment. Furthermore,
societal attitudes towards patients with dementia
could theoretically lead to laxer care procedures.
However, previous studies have shown that the
most important contributor to prehospital delay,
defined as the time between symptom onset and
arrival at the emergency department, is the delay in
seeking medical attention [56, 57]. Studies specif-
ically investigating the influence of dementia on
prehospital care are lacking, but older age and
comorbidity (including previous stroke and demen-
tia) have been shown to contribute to prehospital
delay [56, 57]. Older age was associated with
greater delay in some studies [58], but most
studies found no association [59] and one even
reported shorter time to arrival amongst older
patients [60]. In one study, it was shown that
dementia patients with stroke were more likely to
arrive at the hospital by ambulance [6]. This is
important because arrival by ambulance has been
associated with shorter prehospital delays [59].
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Fig. 2 The association between stroke and dementia: underlying mechanisms.
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The American Heart Association/American Stroke
Association (AHA/ASA) guidelines stipulate a goal
of under 60 min between arrival at the emergency
department and administration of fibrinolysis with
recombinant human tissue plasminogen activator
(tPA), if this treatment is indicated. This window
includes administration of a stroke rating scale
[National Institutes of Health Stroke Scale
(NIHSS)], a noncomprehensive blood work-up,
including a complete blood count, coagulation
and biochemistry, and neuroimaging, often com-
prised of noncontrast computed tomography of the
brain [23]. To our knowledge, there are no data on
performance of acute neuroimaging in dementia
patients with stroke. However, in one study, neu-
roimaging was performed within 24 h in 71% of
patients under 65 years compared to 51% amongst
those older than 85 years [61].
IV thrombolytic therapy
Thrombolysis with IV tPA (alteplase) is approved
within 4.5 h after the onset of stroke symptoms
[10, 23, 24] in patients of any age, although the
AHA/ASA recommends stricter inclusion criteria
for patients in the 3- to 4.5-h time window,
excluding patients >80 years [18, 23].
Dementia is more common in older patients with
stroke, and therefore, age can drive results of
thrombolysis in this group. Contrary to the recom-
mendations for USA, Canada and Switzerland, the
European Medicines Agency (EMA) does not rec-
ommend the use of tPA in patients over 80 years of
age, although the use is accepted in the European
stroke guidelines [24]. This inconsistency is due to
the exclusion of older patients in the early large-
scale European randomized trials of thrombolysis
for stroke [10, 62].
The results of smaller studies comparing symp-
tomatic intracranial haemorrhage (ICH), mortality
rates and overall clinical outcomes between stroke
patients over and under 80 years of age have been
inconsistent [63, 64]. However, thrombolysis sig-
nificantly decreases the risk of mortality following
IS irrespective of age [65, 66].
The safety and efficacy of thrombolysis are not
established in patients with dementia, and the
presence of CMBs poses concerns [40, 41]. In a
meta-analysis of patients with IS treated with
thrombolysis, 9% of patients with CMBs experi-
enced a symptomatic ICH after thrombolysis
compared to 4% without CMBs [40]. Two studies
examined the effect of tPA in aged APP23 trans-
genic mouse models of CAA and found a higher
risk of ICH in the CAA-affected brains [67, 68].
One of these studies also examined mortality
and functional outcomes and found no differ-
ences in APP23 mice compared to control
animals [68].
Dementia is not mentioned in the AHA/ASA or
FDA exclusion criteria. The most recent AHA/ASA
review on criteria for IV tPA use states that
patients with pre-existing dementia may benefit
from IV alteplase, but individual considerations
such as life expectancy and premorbid level of
function are important to determine whether
alteplase may offer a clinically meaningful benefit
[18]. Paciaroni and Pantoni have examined the
use of thrombolysis in dementia, arguing for
careful consideration of the patient’s prior func-
tional level [69].
In practice, due to contraindications and the nar-
row time window, the proportion of patients with IS
who are treated with thrombolysis ranges from 1%
to 16% [6, 70, 71], decreasing to 2–10% of patients
over 80 years [63, 70]. In patients with pre-existing
dementia, thrombolysis ranges from 0.56% to 10%
[6, 72]. The wide range of reported frequencies of
thrombolysis administration is probably due to the
time periods in which the studies were conducted
and differences in care setting (population-based
or stroke unit care).
The treatment of IS with IV tPA in patients with
dementia has never been assessed in a randomized
controlled trial, and future studies withholding
active treatment would now be ethically impossi-
ble. To our knowledge, only three observational
studies have examined safety and efficacy of IV tPA
for treatment of IS in patients with dementia, with
conflicting results. One study retrospectively iden-
tified 153 patients over 80 years of age who had
received IV tPA or intra-arterial reperfusion ther-
apy (IAT) for IS. Of these patients, 21 had prior
dementia, three of whom (14%) presented symp-
tomatic brain haemorrhages, compared to 7% of
nondementia patients [73]. Pre-existing dementia
was found to be a powerful independent predictor
of mortality and poor outcome after IV tPA or IAT
(odds ratio 3.61, 95% confidence interval 1.39–
9.37) [73]. However, outcomes were not compared
in this study between patients with dementia who
did and did not receive IV tPA.
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brain [23]. To our knowledge, there are no data on
performance of acute neuroimaging in dementia
patients with stroke. However, in one study, neu-
roimaging was performed within 24 h in 71% of
patients under 65 years compared to 51% amongst
those older than 85 years [61].
IV thrombolytic therapy
Thrombolysis with IV tPA (alteplase) is approved
within 4.5 h after the onset of stroke symptoms
[10, 23, 24] in patients of any age, although the
AHA/ASA recommends stricter inclusion criteria
for patients in the 3- to 4.5-h time window,
excluding patients >80 years [18, 23].
Dementia is more common in older patients with
stroke, and therefore, age can drive results of
thrombolysis in this group. Contrary to the recom-
mendations for USA, Canada and Switzerland, the
European Medicines Agency (EMA) does not rec-
ommend the use of tPA in patients over 80 years of
age, although the use is accepted in the European
stroke guidelines [24]. This inconsistency is due to
the exclusion of older patients in the early large-
scale European randomized trials of thrombolysis
for stroke [10, 62].
The results of smaller studies comparing symp-
tomatic intracranial haemorrhage (ICH), mortality
rates and overall clinical outcomes between stroke
patients over and under 80 years of age have been
inconsistent [63, 64]. However, thrombolysis sig-
nificantly decreases the risk of mortality following
IS irrespective of age [65, 66].
The safety and efficacy of thrombolysis are not
established in patients with dementia, and the
presence of CMBs poses concerns [40, 41]. In a
meta-analysis of patients with IS treated with
thrombolysis, 9% of patients with CMBs experi-
enced a symptomatic ICH after thrombolysis
compared to 4% without CMBs [40]. Two studies
examined the effect of tPA in aged APP23 trans-
genic mouse models of CAA and found a higher
risk of ICH in the CAA-affected brains [67, 68].
One of these studies also examined mortality
and functional outcomes and found no differ-
ences in APP23 mice compared to control
animals [68].
Dementia is not mentioned in the AHA/ASA or
FDA exclusion criteria. The most recent AHA/ASA
review on criteria for IV tPA use states that
patients with pre-existing dementia may benefit
from IV alteplase, but individual considerations
such as life expectancy and premorbid level of
function are important to determine whether
alteplase may offer a clinically meaningful benefit
[18]. Paciaroni and Pantoni have examined the
use of thrombolysis in dementia, arguing for
careful consideration of the patient’s prior func-
tional level [69].
In practice, due to contraindications and the nar-
row time window, the proportion of patients with IS
who are treated with thrombolysis ranges from 1%
to 16% [6, 70, 71], decreasing to 2–10% of patients
over 80 years [63, 70]. In patients with pre-existing
dementia, thrombolysis ranges from 0.56% to 10%
[6, 72]. The wide range of reported frequencies of
thrombolysis administration is probably due to the
time periods in which the studies were conducted
and differences in care setting (population-based
or stroke unit care).
The treatment of IS with IV tPA in patients with
dementia has never been assessed in a randomized
controlled trial, and future studies withholding
active treatment would now be ethically impossi-
ble. To our knowledge, only three observational
studies have examined safety and efficacy of IV tPA
for treatment of IS in patients with dementia, with
conflicting results. One study retrospectively iden-
tified 153 patients over 80 years of age who had
received IV tPA or intra-arterial reperfusion ther-
apy (IAT) for IS. Of these patients, 21 had prior
dementia, three of whom (14%) presented symp-
tomatic brain haemorrhages, compared to 7% of
nondementia patients [73]. Pre-existing dementia
was found to be a powerful independent predictor
of mortality and poor outcome after IV tPA or IAT
(odds ratio 3.61, 95% confidence interval 1.39–
9.37) [73]. However, outcomes were not compared
in this study between patients with dementia who
did and did not receive IV tPA.
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The second study in 2011 was a case–control study
including 207 patients with dementia who had
received IV tPA. The authors found no differences
in risk of ICH (6% vs. 5%) or hospital mortality
(17% vs. 15%) between patients with and without
dementia [72]. However, the extremely low rate of
IV tPA administration (0.56%) amongst patients
with dementia could imply that only atypically
healthy candidates were treated, leading to possi-
ble underestimation of the bleeding risk.
The third study was a multicentre study including
patients treated at 12 Canadian hospitals between
2003 and 2008 [6]. A total of 702 patients with
dementia were compared with control patients
without dementia: 74 patients with dementia
(11%) had received IV tPA, compared to 1352
controls (16%; P < 0.001) [6]. From this cohort, a
matched case–control study was conducted with
877 pairs of stroke patients with and without
dementia; almost the same proportion of patients
with dementia compared to controls had received
IV tPA [11.3% (n = 99) vs. 11.5% (n = 101), respec-
tively; P = 0.88] [74]. Mortality (22% for patients
with dementia vs. 26%) and bleeding risk (19% vs.
15%) did not differ from control patients without
dementia, although there was a trend towards
greater functional disability [modified Rankin scale
(mRS) score of 3–5 in 68% vs. 56%).
The results of these three studies are contradic-
tory. However, in the two larger studies in which
patients with dementia were matched with
dementia-free controls, there were no significant
differences in risks of ICH and mortality rates
(Table 1) [72, 74].
Endovascular treatment
The limitations of IV tPA treatment, such as narrow
therapeutic time window, and its contraindica-
tions, including coagulopathy, recent surgery or
head injury [23], have led to interest in endovas-
cular therapy for acute IS. Between December
2014 and April 2015, five randomized controlled
trials provided compelling evidence that intra-
arterial thrombectomy (IAT) improves outcomes in
some instances of acute IS [75–79]. Endovascular
treatment significantly improved clinical outcome
in patients with proximal intracranial occlusion of
the anterior circulation compared with IV tPA [80,
81]. In these studies, dementia was not mentioned
specifically as an exclusion criterion, although
subjects were excluded if they had comorbid
conditions that would confound the neurological
and functional evaluation or compromise survival.
Two studies excluded patients >80 years of age [75,
76], and the other three did not set an upper age
limit [77–79].
Supportive care and postacute treatment
One of the most important advances in the treat-
ment of stroke is the routine management of
patients in stroke care units [82]. All groups of
patients, irrespective of sex, age and stroke sub-
type and severity, appear to benefit from treatment
in stroke units [17]. In one study, it was found that
patients with dementia were slightly less likely to
be admitted to a stroke unit than those without
dementia (63% vs. 68%; P = 0.012) [6].
Carotid imaging has been reported to be less
common in older patients [61]. Similarly, lower
use of carotid imaging was shown in stroke
patients with pre-existing dementia (65% vs.
81%; P < 0.001) [6].
Patients with dementia may be slightly more likely
to receive swallowing assessments (71% vs. 68%;
P = 0.05) [6]; similarly older patients with stroke
may also undergo such assessment more fre-
quently [61, 83]. Fewer invasive interventions are
performed in stroke patients with dementia; one
study showed a lower incidence of endotracheal
intubation in the dementia compared to the
nondementia population (3% vs. 11%) [72]. Gen-
eral supportive care, including cardiac monitor-
ing, treatment of elevated blood pressure,
lowering of fever and diagnosis of infection, and
treatment of hyper- and hypoglycaemia [23] have
not been specifically investigated in patients with
dementia.
Secondary stroke prevention
The rate of stroke recurrence is between 13% and
32% within 5 years of the first stroke, and a
subsequent event is frequently more disabling
and fatal than the first [84, 85]. Consequently,
effective secondary stroke prevention strategies are
needed. The cornerstones of secondary stroke
prevention are antiplatelet therapy, treatment of
hypertension, atrial fibrillation (AF), diabetes and
hyperlipidaemia, management of lifestyle risk fac-
tors and early carotid revascularization in patients
with ipsilateral severe carotid artery stenosis [86,
87].
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Adherence to pharmacological secondary preven-
tion may be lower in patients with dementia. In an
observational study of compliance to medication,
the risk of noncompliance was significantly higher
in patients with cognitive impairment, particularly
in those who lived alone [49]. However, as dis-
cussed above, compliance can depend on disease
stage, improving in severe dementia after care-
givers take over responsibility for medication [53].
Antiplatelet therapy. Antiplatelet therapy is part of
the standard management of stroke. Oral admin-
istration of acetylsalicylic acid (ASA) at a dose of
325 mg is recommended within the first 24 h of
acute IS, as the evidence for clopidogrel is less well
established [23]. Antiplatelet agents are a corner-
stone of secondary prevention for noncardioem-
bolic stroke, with ASA (alone or combined with
dipyridamole) or clopidogrel being the most fre-
quently used alternatives [88].
There are concerns of an increased risk of cerebral
haemorrhage with ASA in patients with AD [89].
Two randomized placebo-controlled trials have
been performed to examine the ability of ASA to
prevent cognitive decline in AD, and results were
combined for a meta-analysis [89]. Both trials were
relatively small, but the risk of ICH was 2.6% and
4.6% in patients treated with ASA compared to 0%
in the placebo groups, suggesting increased risk
[89]. There is no evidence for an effect of ASA on
cognitive decline [90]. For this reason, given the risk
of ICH, ASA should not be prescribed to AD patients
without cardiovascular disease risk factors with the
sole intent of slowing cognitive decline.
Of interest, the consensus is that in AD patients
with previous stroke, benefit as secondary preven-
tion would supersede the increased bleeding risk,
even though no randomized placebo-controlled
trials have been carried out in this setting. ASA is
widely prescribed for patients with vascular
dementia. In one study, almost 80% of patients
with vascular disease risk factors and dementia
received ASA [91]. To our knowledge, there is no
evidence to support any particular choice of
antiplatelet agent specifically in patients with
dementia.
Anticoagulation in AF. Anticoagulation therapy
with warfarin or novel oral anticoagulants (NOACs)
is indicated for the prevention of recurrent
stroke in patients with AF [17, 86]. Patients with
dementia are significantly less likely to receive
these treatments for prevention of recurrent stroke
[92–94]. Presumably, the underuse of oral antico-
agulants (OACs) in stroke patients with dementia
reflects physicians’ concerns of greater risks
resulting from inconsistent compliance or falls.
Fear regarding anticoagulation for institutionalized
older adults with AF and concerns about the risks
of bleeding and/or falls tended to outweigh any
perceived benefit in terms of stroke prevention [95].
However, in the RELA study in which a decision
analysis model was used, it was estimated that an
older patient would need to fall 295 times in 1 year
to offset the stroke reduction benefits of warfarin
[96].
Despite this, the American Academy of Neurology
guidelines for stroke prevention in AF state that
data in patients with AF who have moderate-to-
severe dementia are insufficient to determine
whether anticoagulants are safe or effective [97].
European Stroke Organisation (ESO) guidelines do
not specifically contraindicate the use of OACs in
patients with dementia, but do not recommend
their use in patients with comorbid conditions
such as falls or poor compliance [17]. However,
studies that investigated the use of warfarin for
prevention of thromboembolism in AF in different
age groups have shown a higher rate of bleeding in
the older population, but also a higher rate of IS
which would indicate a greater need for anticoag-
ulation (Table 2) [98–108]. However, older patients
(>75/80 years) in these studies are significantly
under-represented.
In this context, it is understandable that physi-
cians are hesitant to treat patients with dementia
with anticoagulants. Data on the use of NOACs in
this patient population are also lacking.
Treatment of dyslipidaemia. Statin use is an impor-
tant component in the secondary prevention of IS
[86]. However, it has been shown that in patients
with a history of cerebrovascular disease, this
effect is partially counterbalanced by an increase
in the occurrence of haemorrhagic stroke, suppos-
edly related to low cholesterol levels [109]. This
risk, however, does not offset the benefits of
treatment.
For patients over 75 years, guidelines recommend
assessing the benefits and adverse effects before
initiating moderate-intensity statin therapy, irre-
spective of dementia status [110]. There are also
some reports of statins causing impaired cognition
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[111–113], which would be a consideration in
patients with dementia.
Underprescription in patients with pre-existing
dementia compared with controls has also been
reported for statins (64% vs. 71%) [6]. Information
is lacking on the impact of statin use on mortality
and secondary stroke prevention specifically in
patients with dementia.
Rehabilitation and care after discharge
Cognitive impairment after stroke is associated
with higher mortality, greater rates of institu-
tionalization and greater costs, so it is reason-
able to suppose that the same would be true for
patients with dementia prior to stroke [114–116].
The impact of cognition on functional outcomes
has been extensively studied in older patients
admitted to rehabilitation units [117–122].
Because cognition is important for recovery of
other neurological domains, patients with higher
cognitive status on admission to rehabilitation
had better functional outcomes and required
shorter periods of rehabilitation [123]. However,
all these studies found significant improvement
in functional outcomes also in patients with
cognitive impairment [117–123]. It was shown
that home discharge after rehabilitation was
possible for many such patients. For example,
Rabadi et al. [122] reported home discharge for
78% of cognitively intact stroke patients, 73% of
mildly impaired, 57% of moderately impaired
and 43% of severely impaired patients. They also
showed that change in functional independence
was influenced by admission Functional Inde-
pendence Measure score and age, but not by
cognition on admission. Saposnik et al. [6] also
showed that patients with dementia were more
likely to receive physiotherapy during hospital-
ization (91% vs. 87%).
Functional outcomes and survival
Prestroke dementia is associated with worse out-
comes [8, 72–74, 124]. Patients with dementia were
less likely compared to those without dementia to
be discharged from hospital to their home (18.7%
vs. 40.5%) [74]. A higher rate of disability at
discharge has also been reported (64% vs. 59%)
[74].
Older patients with stroke presented higher mor-
tality, irrespective of treatment [125]. Several
studies have demonstrated an approximately two-
fold increase in mortality with stroke in patients
with pre-existing dementia irrespective of age [8,
72, 124]. Prestroke dependency was also associ-
ated with higher risk of ICH, poor functional
outcomes and death after thrombolysis [126].
Amongst those treated with reperfusion therapy,
the in-hospital mortality rate amongst patients
≥80 years was around 35% [73, 127]. Results
regarding reperfusion therapy in patients with
dementia have been inconsistent. Saposnik et al.
[74] showed no differences in survival at discharge,
30 days or 1 year after IV tPA between patients
with and without dementia. In a study by Alshekh-
lee et al. [72], thrombolysis did not increase the
risk of death (17.4% vs. 14.5%; P = 0.31) in
patients with dementia compared to the controls
(Table 1).
In a study including patients with and without
dementia, it was found that the presence of
prestroke disability (not necessarily caused by
dementia) was correlated with poor prognosis after
treatment with tPA [126]. In fact, patients with a
prestroke mRS score of 3–5 had a very poor
prognosis in terms of mortality and disability
(60.5%), compared to patients with an mRS score
of 0–2 (39.6%). There was no observed increase in
risk of haemorrhagic transformation in either
group (4.8% vs. 4.5%), suggesting that prestroke
disability may be more relevant in terms of the final
outcome than the risk of haemorrhage.
Ethical issues
Providing high-quality care for the old consists of
adhering to the basic principles of medical ethics,
which include autonomy, beneficence, nonmalfea-
sance and justice [128]. These principles describe
the ideal healthcare relationship between patient
and physician with regard to the assessment of
evidence and care. Applying these principles to
patients with dementia experiencing IS highlights
the limitations of the healthcare system, evidence-
based findings and societal views on ageing and
dementia. A recent survey amongst neurologists for
example showed that they were less likely to
administer IV tPA to patients with dementia (79%)
and many were less likely to treat patients from
nursing homes or those with more severe strokes
or over 80 years of age [129]. The findings of this
survey suggest that neurologists’ decisions about
IV tPA are affected by considerations about quality
of life and expected prognosis. Economic
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dementia compared with controls has also been
reported for statins (64% vs. 71%) [6]. Information
is lacking on the impact of statin use on mortality
and secondary stroke prevention specifically in
patients with dementia.
Rehabilitation and care after discharge
Cognitive impairment after stroke is associated
with higher mortality, greater rates of institu-
tionalization and greater costs, so it is reason-
able to suppose that the same would be true for
patients with dementia prior to stroke [114–116].
The impact of cognition on functional outcomes
has been extensively studied in older patients
admitted to rehabilitation units [117–122].
Because cognition is important for recovery of
other neurological domains, patients with higher
cognitive status on admission to rehabilitation
had better functional outcomes and required
shorter periods of rehabilitation [123]. However,
all these studies found significant improvement
in functional outcomes also in patients with
cognitive impairment [117–123]. It was shown
that home discharge after rehabilitation was
possible for many such patients. For example,
Rabadi et al. [122] reported home discharge for
78% of cognitively intact stroke patients, 73% of
mildly impaired, 57% of moderately impaired
and 43% of severely impaired patients. They also
showed that change in functional independence
was influenced by admission Functional Inde-
pendence Measure score and age, but not by
cognition on admission. Saposnik et al. [6] also
showed that patients with dementia were more
likely to receive physiotherapy during hospital-
ization (91% vs. 87%).
Functional outcomes and survival
Prestroke dementia is associated with worse out-
comes [8, 72–74, 124]. Patients with dementia were
less likely compared to those without dementia to
be discharged from hospital to their home (18.7%
vs. 40.5%) [74]. A higher rate of disability at
discharge has also been reported (64% vs. 59%)
[74].
Older patients with stroke presented higher mor-
tality, irrespective of treatment [125]. Several
studies have demonstrated an approximately two-
fold increase in mortality with stroke in patients
with pre-existing dementia irrespective of age [8,
72, 124]. Prestroke dependency was also associ-
ated with higher risk of ICH, poor functional
outcomes and death after thrombolysis [126].
Amongst those treated with reperfusion therapy,
the in-hospital mortality rate amongst patients
≥80 years was around 35% [73, 127]. Results
regarding reperfusion therapy in patients with
dementia have been inconsistent. Saposnik et al.
[74] showed no differences in survival at discharge,
30 days or 1 year after IV tPA between patients
with and without dementia. In a study by Alshekh-
lee et al. [72], thrombolysis did not increase the
risk of death (17.4% vs. 14.5%; P = 0.31) in
patients with dementia compared to the controls
(Table 1).
In a study including patients with and without
dementia, it was found that the presence of
prestroke disability (not necessarily caused by
dementia) was correlated with poor prognosis after
treatment with tPA [126]. In fact, patients with a
prestroke mRS score of 3–5 had a very poor
prognosis in terms of mortality and disability
(60.5%), compared to patients with an mRS score
of 0–2 (39.6%). There was no observed increase in
risk of haemorrhagic transformation in either
group (4.8% vs. 4.5%), suggesting that prestroke
disability may be more relevant in terms of the final
outcome than the risk of haemorrhage.
Ethical issues
Providing high-quality care for the old consists of
adhering to the basic principles of medical ethics,
which include autonomy, beneficence, nonmalfea-
sance and justice [128]. These principles describe
the ideal healthcare relationship between patient
and physician with regard to the assessment of
evidence and care. Applying these principles to
patients with dementia experiencing IS highlights
the limitations of the healthcare system, evidence-
based findings and societal views on ageing and
dementia. A recent survey amongst neurologists for
example showed that they were less likely to
administer IV tPA to patients with dementia (79%)
and many were less likely to treat patients from
nursing homes or those with more severe strokes
or over 80 years of age [129]. The findings of this
survey suggest that neurologists’ decisions about
IV tPA are affected by considerations about quality
of life and expected prognosis. Economic
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considerations may also influence decision-mak-
ing. Whilst patients with dementia deserve to be
treated with the best medical care, this care may
not always mean heightened intervention. In the
final stages, dementia can be considered a pallia-
tive disease, and then, it may not be justifiable to
administer aggressive treatments such as IV tPA
[129]. This contrasts with the experience of
patients in earlier disease stages where withhold-
ing treatment is not appropriate. Ethical issues
may arise when clinical practice is based upon
studies that purposefully excluded patients with
dementia [129].
The principle of autonomy emphasizes a patient’s
right to self-determination in choosing treatments
most likely to result in a preferred health outcome,
but only a minority of patients are able to give
consent at the acute stage of stroke [130].
Conclusions
The care of patients with dementia raises medical,
organizational and ethical issues. Management of
IS in older subjects and those with dementia
remains controversial. Further research is needed
to fully establish and adapt therapeutic protocols
to this population (Fig. 3). As noted in the latest
AHA/ASA review on criteria for IV tPA use, treat-
ment of patients with pre-existing dementia who
experience an IS is a high-priority area for research
[18]. We agree with the opinion that age alone
Prehospital stroke care:
– Description of chain of care in dementia, differences with nondementia patients and 
impact on prognosis.
– Interventions to improve chain of care.
Rehabilitation:
– Access to and effects of rehabilitation.
– Identification of patient groups with dementia who benefit from rehabilitation.
General:
– Underdiagnosis of stroke in patients with dementia.
– Cost/benefit of interventions. 
– Relevant prognostic outcomes include mortality, cognitive decline, repeated stroke, place 
of discharge after hospitalization and time to institutionalization in patients originally 
discharged home.
– Acceptability of interventions for patients and their relatives. Patient and caregiver 
satisfaction with interventions.
Secondary prevention:
– Choice of anti-agreggation.
– Choice of statin.
– Warfarin in atrial fibrillation. Which patients benefit?
In-hospital care:
– Compliance with current guidelines and in-hospital stroke protocols in patients with 
dementia.
– How does stroke hospitalization (general neurology unit, specialized stroke unit, geriatric 
unit) impact patient outcomes?
• Which groups of patients with dementia depending on dementia type, 
stroke or dementia severity benefit from stroke units?
• Prevention of delirium.
– Do some aspects of routine stroke care particularly benefit patients with dementia? For 
example: environmental modifications, timing of ancillary procedures.
– Safety and efficacy of thrombolysis in patients with dementia. Patient selection in this 
collective.
• Refining relevant animal models. 
– Is thrombectomy safer in patients with dementia?
Fig. 3 Management of stroke in patients with pre-existing dementia: future research directions.
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should not be an exclusion criteria for IV tPA use,
and neither should mild pre-existing dementia,
unless this treatment is precluded because of other
reasons. However, not all patients with dementia
are clinically suitable candidates for all interven-
tions, making it critical to target the right popula-
tions. Further research would need to find models
to predict the risks and benefits of treatment with
IV tPA in patients with dementia, taking into
account previous functional level [18, 69, 126].
A further issue is the focus on thrombolysis, which
could distort the chain of care for patients who are
not candidates for this intervention. A clearer
understanding of how different interventions affect
outcomes can lead to tailoring interventions to
particular patients. Furthermore, patients with
dementia are a heterogeneous group, with different
diagnoses (putatively associated with different
neuropathological processes) and varying levels of
cognition and functioning. This creates the need for
research focusing on different patient subgroups
and requires individualized care decisions [69].
With regard to oral anticoagulation, underuse in
patients with AF is a problem amongst older
populations, particularly those with dementia.
However, it is unclear whether the scoring systems
(such as HAS-BLED and CHA2DS2VASc) [131,
132] used to predict stroke and bleeding risks are
translatable to dementia populations, and this
needs to be explored in future research.
At present, it would be technically and ethically
difficult to conduct placebo-controlled trials of
thrombolysis in patients with dementia, and the
same is true for other treatments, such as warfarin
or hospitalization in stroke units, which are estab-
lished for other patient groups. Observational
studies in large clinical cohorts, including quality
registries, could be an important first step in
determining which interventions are associated
with better outcomes for patients with different
types of dementia and at different disease stages.
Animal models of AD could be used to examine the
safety of certain treatments. However, this requires
a clear hypothesis to explain the mechanisms of
effect as currently no existing animal models
present all the pathophysiological changes
observed in human AD.
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should not be an exclusion criteria for IV tPA use,
and neither should mild pre-existing dementia,
unless this treatment is precluded because of other
reasons. However, not all patients with dementia
are clinically suitable candidates for all interven-
tions, making it critical to target the right popula-
tions. Further research would need to find models
to predict the risks and benefits of treatment with
IV tPA in patients with dementia, taking into
account previous functional level [18, 69, 126].
A further issue is the focus on thrombolysis, which
could distort the chain of care for patients who are
not candidates for this intervention. A clearer
understanding of how different interventions affect
outcomes can lead to tailoring interventions to
particular patients. Furthermore, patients with
dementia are a heterogeneous group, with different
diagnoses (putatively associated with different
neuropathological processes) and varying levels of
cognition and functioning. This creates the need for
research focusing on different patient subgroups
and requires individualized care decisions [69].
With regard to oral anticoagulation, underuse in
patients with AF is a problem amongst older
populations, particularly those with dementia.
However, it is unclear whether the scoring systems
(such as HAS-BLED and CHA2DS2VASc) [131,
132] used to predict stroke and bleeding risks are
translatable to dementia populations, and this
needs to be explored in future research.
At present, it would be technically and ethically
difficult to conduct placebo-controlled trials of
thrombolysis in patients with dementia, and the
same is true for other treatments, such as warfarin
or hospitalization in stroke units, which are estab-
lished for other patient groups. Observational
studies in large clinical cohorts, including quality
registries, could be an important first step in
determining which interventions are associated
with better outcomes for patients with different
types of dementia and at different disease stages.
Animal models of AD could be used to examine the
safety of certain treatments. However, this requires
a clear hypothesis to explain the mechanisms of
effect as currently no existing animal models
present all the pathophysiological changes
observed in human AD.
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  Povzetek 
Uvod: Bolniki z demenco naj bi imeli višje tveganje za hemoragične zaplete na 
antiakoagulantnem zdravljenju, predpisanem za atrijsko fibrilacijo.  
Cilji: Namen študije je bil preučiti tveganje in učinkovitost antikoagulantnega zdravljenja z 
varfarinom za zdravljenje atrijske fibrilacije pri bolnikih z demenco in ga primerjati z 
antiagregacijskim zdravljenjem in tistimi brez antitrombotičnega zdravljenja. 
Rezultati: Med 8.096 bolniki z diagnozo demence in atrijske fibrilacije, je bilo zdravljenih z 
varfarinom 2.143 (26%) bolnikov, 2.975 (37%) jih je prejemalo antiagregacijsko zdravljenje 
in 2.978 (37%) ni prejemalo antitrombotičnega zdravljenja v času diagnoze demence. Bolniki, 
zdravljeni z varfarinom, so imeli manj ishemičnih možganskih kapi v primerjavi z bolniki brez 
antitrombotične terapije (5,2% vs. 8,7%; p<0,001), medtem ko v primerjavi z bolniki z 
antiagregacijsko terapijo ni bilo statistično pomembnih razlik. Terapija z varfarinom je bila 
povezana z manjšim tveganjem za ishemično možgansko kap (HR=0,76, CI 0.59–0.98), 
medtem ko je bila antiagregacijska terapija povezana z višjim tveganjem za ishemično 
možgansko kap (HR 1,25, CI 1.01–1.54) v primerjavi z bolniki brez terapije. Pri bolnikih z 
varfarinom je bilo višje tveganje za krvavitev v primerjavi z bolniki z antiagregacijsko terapijo 
(HR=1,28, p=0,027). Zdravljenje z varfarinom in z antiagregacijsko terapijo je bilo povezano 
z manjšo umrljivostjo v primerjavi z bolniki brez terapije.  
Zaključki: Antiakoagulantno zdravljenje z varfarinom pri švedskih bolnikih z demenco je bilo 
povezano z manjšim tveganjem za ishemično možgansko kap in za umrljivost ter z majhnim 
tveganjem za krvavitev v primerjavi z bolniki brez terapije. Rezultati te raziskave podpirajo 
uporabo varfarina pri izbranih bolnikih z demenco. Nizek odstotek bolnikov zdravljenih z 
varfarinom kaže na možnosti izboljšave pri preventivi ishemične možganske kapi. 
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Objective: This study assesses the risks and benefits of warfarin, antiplatelets, and no treatment in patients with dementia
and AF.
Methods: Of 49,792 patients registered in the Swedish Dementia Registry 2007–2014, 8,096 (16%) had a previous diagnosis
of AF. Cox proportional hazards models were used to calculate the risk for ischemic stroke (IS), nontraumatic intracranial
hemorrhage, any-cause hemorrhage, and death.
Results: Out of the 8,096 dementia patients with AF, 2,143 (26%) received warfarin treatment, 2,975 (37%) antiplatelet
treatment, and 2,978 (37%) had no antithrombotic treatment at the time of dementia diagnosis. Patients on warfarin had fewer
IS than those without treatment (5.2% versus 8.7%; p< 0.001) with no differences compared to antiplatelets. In adjusted
analyses, warfarin was associated with a lower risk for IS (HR 0.76, CI 0.59–0.98), while antiplatelets were associated
with increased risk (HR 1.25, CI 1.01–1.54) compared to no treatment. For any-cause hemorrhage, there was a higher risk with
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Abstract.
Background: Patients with dementia might have higher risk for hemorrhagic complications with anticoagulant therapy
prescribed for atrial fibrillation (AF).
Objective: This study assesses the risks and benefits of warfarin, antiplatelets, and no treatment in patients with dementia
and AF.
Methods: Of 49,792 patients registered in the Swedish Dementia Registry 2007–2014, 8,096 (16%) had a previous diagnosis
of AF. Cox proportional hazards models were used to calculate the risk for ischemic stroke (IS), nontraumatic intracranial
hemorrhage, any-cause hemorrhage, and death.
Results: Out of the 8,096 dementia patients with AF, 2,143 (26%) received warfarin treatment, 2,975 (37%) antiplatelet
treatment, and 2,978 (37%) had no antithrombotic treatment at the time of dementia diagnosis. Patients on warfarin had fewer
IS than those without treatment (5.2% versus 8.7%; p< 0.001) with no differences compared to antiplatelets. In adjusted
analyses, warfarin was associated with a lower risk for IS (HR 0.76, CI 0.59–0.98), while antiplatelets were associated
with increased risk (HR 1.25, CI 1.01–1.54) compared to no treatment. For any-cause hemorrhage, there was a higher risk with
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warfarin (HR 1.28, CI 1.03–1.59) compared to antiplatelets. Warfarin and antiplatelets were associated with a lower risk for
death compared to no treatment.
Conclusions: Warfarin treatment in Swedish patients with dementia is associated with lower risk of IS and mortality, and
a small increase in any-cause hemorrhage. This study supports the use of warfarin in appropriate cases in patients with
dementia. The low percentage of patients on warfarin treatment indicates that further gains in stroke prevention are possible.
Keywords: Atrial fibrillation, dementia, hemorrhage, ischemic stroke, warfarin
INTRODUCTION
Atrial fibrillation (AF) is the most common car-
diac arrhythmia and its prevalence increases with
age appearing in 10% of those older than 80
years [1]. AF is responsible for about 20% of all
ischemic strokes (IS) [2]. The risk of stroke is
increased in patients with dementia, [3] represent-
ing an important cause of morbidity and death [4,
5]. Oral anticoagulant (OAC) therapy, traditionally
warfarin, is used to prevent stroke in patients with
AF. Previous studies have shown that adjusted-dose
warfarin is more effective than aspirin at reducing
IS, but increases bleeding complications [6–8]. How-
ever, patients with dementia have often been excluded
from studies establishing the benefit of warfarin and
there are still few studies on stroke prevention and
treatment in this population [9].
Warfarin may be underused or inconsistently pre-
scribed in older patients with dementia [10]. Old
age and dementia are associated with greater risk for
hemorrhagic complications through different mech-
anisms, including falls, and polypharmacy leading to
interactions with warfarin metabolism. Leukoaraiosis
and cerebral amyloid angiopathy have been asso-
ciated with higher risk for intracranial hemorrhage
(ICH) [9]. Similar mechanisms may also explain the
suggested increased ICH rate for aspirin treatment in
patients with dementia [11].
For these reasons, the American Academy of Neu-
rology guidelines for stroke prevention in AF state
that data in patients with AF who have moderate to
severe dementia are insufficient to determine whether
anticoagulants are safe [12]. European Stroke Organ-
isation guidelines do not specifically contraindicate
OAC in dementia patients, but do not recommend
them in patients with co-morbid conditions such as
falls or poor compliance [13]. The European Society
of Cardiology guidelines do not consider dementia
to be a contraindication for anticoagulation unless
compliance cannot be ensured [14].
The present cohort study aims to assess the risks
and benefits of OAC and antiplatelet use for stroke
prevention in AF in patients with dementia, and
evaluate the association between treatment and risk
of ischemic and hemorrhagic stroke, any-cause hem-
orrhage, and death.
METHODS
We performed a longitudinal cohort study on
patients registered in the Swedish Dementia Reg-
istry (SveDem). Information on AF, treatment, and
comorbidities was obtained from the Swedish Patient
Register and the Swedish Prescribed Drug Regis-
ter. Data on death was obtained from the Swedish
Population Register.
This study complies with the Declaration of
Helsinki and was approved by the regional ethi-
cal review board in Stockholm, Sweden. Patients
were informed of registration in SveDem and could
decline participation. Data were de-identified before
analysis.
Study population
SveDem is a national registry that aims to improve
the quality of diagnostic workup, treatment, and care
of patients with dementia in Sweden. The registration
process and variables in SveDem have been previ-
ously described [15, 16]. Briefly, patients with newly
diagnosed dementia are registered by physicians in
specialist or primary care together with demographic
and treatment variables. For this study, the diag-
noses were classified as Alzheimer’s dementia (AD),
vascular dementia, mixed Alzheimer’s and vascular
dementia, or other dementia disorders. Information
on age, sex, Mini-Mental State Examination (MMSE)
score, and living conditions was obtained from Sve-
Dem at the time of dementia diagnosis.
Information about co-morbidities occurring from
1998 until the end of 2014 coded according to Inter-
national Classification of Diseases 10 (ICD-10) [17]
was collected from the Swedish Patient Register. This
register covers inpatient and outpatient specialist care
encounters in Sweden [18]. Patients with AF were
identified by the code I48 present either as main
or contributory diagnosis at any point between the
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year 1998 and the date of dementia diagnosis. Other
comorbidities identified as either main or contribu-
tory diagnosis from 1998 until the time of dementia
diagnosis were diabetes mellitus (E10-E13), hyper-
tension (I10-I15), liver diseases (K70-77), kidney
diseases (N10-19), heart failure (I50), presence of
cardiac pacemaker (Z950, DF016, DF014, FPE, FPF,
FPG, FPJ, DZXG40, or ZXG50), and ischemic heart
disease (I20-I25).
Furthermore, previous main diagnoses of stroke
of any type (I64), IS (I63), nontraumatic ICH (I60-
I62), and traumatic ICH (S063-S068) from 1998
until the time of dementia diagnosis were identi-
fied. A composite variable of main diagnoses of
systemic and intracranial hemorrhage, both traumatic
and spontaneous was considered (any-cause hem-
orrhage). Any-cause hemorrhage included traumatic
ICH (S063-S068); nontraumatic ICH (I60-I62); hem-
orrhage from respiratory passages (R04); anemia
(D50 and D62); hemorrhage unspecified (R58); gas-
trointestinal bleeding (K92); and traumatic shock
(T794). For outcomes, we used a record of the disease
occurring as main diagnosis after the date of demen-
tia diagnosis: IS (ICD-10 I63), nontraumatic ICH
(ICD-10 I60-I62), any-cause hemorrhage (described
above), and death (obtained from the Swedish Death
Register).
Drug use 2005–2014 was obtained from the
Swedish Prescribed Drug Register, which includes
all prescription-drugs dispensed to a patient in any
pharmacy in Sweden [19]. For each individual, a med-
ication list at the date of measure was constructed
according to the filled prescriptions registered in
the Swedish Prescribed Drug Register during the
three month period preceding the date of dementia
diagnosis.
Drugs were coded according to the Anatomical
Therapeutic Chemical classification system: acetyl-
salicylic acid (B01AC06, N02BA01, N02BA51),
warfarin (B01AA03), and clopidogrel (B01AC04).
Patients treated with novel oral anticoagulants
(NOACs) were excluded because these treatments
were uncommon in Sweden during the study period.
The following groups of treatment were considered:
1) patients receiving only warfarin treatment at the
time of dementia diagnosis (patients with coexisting
antiplatelet treatment were excluded), 2) patients with
only antiplatelet treatment (receiving only aspirin,
only clopidogrel or combination of aspirin with
clopidogrel), and 3) patients without any antiplatelet
or anticoagulant treatment. Drug prescription was
decided by their physician and was not random-
ized. The number of habitual drugs taken at the
time of dementia diagnosis was used as a proxy for
comorbidity, calculated after excluding warfarin and
antiplatelets [16, 20].
Statistical analyses
From 49,792 patients, 8,485 (17%) had a diagno-
sis of AF. After exclusion of patients who used both
antiplatelets and warfarin or other kinds of anticoagu-
lants, the final study sample of patients with dementia
and AF was 8,096 (Fig. 1). Baseline characteristics
of the patients at the time of dementia diagnosis
and the outcomes during follow-up were compared
between treatment groups using chi-square test or
T-test. Descriptives are shown as means± standard
Fig. 1. Selection of the study sample.
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deviation (SD), median and interquartile range (IQR),
or frequency (number—n and percentage–%), as
appropriate.
Survival analyses to identify factors associated
with risk for IS, ICH, any-cause hemorrhage, and
death were performed using Cox proportional haz-
ards regression models to estimate hazard ratios
(HR) with 95% confidence intervals (CI). The pro-
portionality of hazards was checked using visual
procedures. Models adjusted for age and sex were
performed. Subjects with observation time <1 day
were excluded (n= 6). The final adjusted models were
arrived at by testing any variables that presented base-
line differences between the groups with p< 0.25
in univariate comparisons and other variables previ-
ously shown to affect mortality in Swedish patients
with dementia [16]: variables were then kept in the
survival models if they were significant and/or sub-
stantially improved the model. The final models were
adjusted for age, sex, number of medication, MMSE,
dementia type (AD versus others), nursing home
placement, and previous diagnosis of diabetes, hyper-
tension, heart failure, IS, any-cause hemorrhage, liver
diseases, and kidney diseases. Models were repeated
for all four outcomes: IS, ICH, any-cause hemor-
rhage, and death. Adjusted and unadjusted models
for all four outcomes were repeated with stratifica-
tion by sex, previous pacemaker, previous IS, and
previous any-cause hemorrhage. We performed post-
hoc propensity score adjusted models. These were
obtained from multiple logistic regression includ-
ing the variables age, sex, number of medication,
MMSE, dementia type (AD versus others), nurs-
ing home placement, previous diagnosis of diabetes,
hypertension, heart failure, pacemaker IS, any-cause
hemorrhage, anemia, gastrointestinal bleeding, hip
fracture, liver diseases, and kidney diseases. The
interactions between number of medications and liver
or kidney diseases were tested. Two linear splines
with a node at 79 years (sample median) were used for
age, while MMSE and number of drugs were entered
as linear variables. Comorbidities were entered as
dichotomous variables as described above.
Two tailed p< 0.05 was considered to be sta-
tistically significant in all analytical procedures.
Analyses were performed using the Statistical Pack-
age for the Social Sciences software version 22 (IBM
Corporation, Armonk, NY, USA) and STATA® ver-
sion 12.1 (StataCorp, College Station, TX, USA).
RESULTS
This study included 8,096 patients with demen-
tia and AF (82 years old; 52% women; Table 1).
At the time of dementia diagnosis, 2,143 (26%)
patients received warfarin, 2,975 (37%) antiplatelets,
and 2,978 (37%) neither antiplatelet nor anticoagu-
lant treatment. Patients on warfarin were younger (81
years versus 83 antiplatelet versus 82 years no treat-
ment, p< 0.001), less frequently women (48% versus
52% in the antiplatelet group and 55% in no-treatment
groups; p< 0.001), and had higher MMSE (22 versus
21 patients with antiplatelets or without treatment;
p< 0.001). Patients were followed up for a median of
636 days (IQR 805) until death or the end of 2014.
During the follow-up, 111 (5.2%) IS occurred
in the warfarin group, compared to 180 (6.0%) in
Table 1
Baseline characteristics of study population
AF present at the time of Patients without Patients treated p-value for Patients with p-value
dementia diagnosis (N= 8,096) treatment with warfarin dif. to no antiplatelet treatment for dif. to
(n= 2,978; 37%) (n= 2,143; 27%) treatment (n= 2,975; 37%) warfarin
Age at diagnosis (mean± SD) 82.3± 6.5 80.8± 5.8 <0.001 83.3± 6.2 <0.001
Female gender, n (%) 1544 (51.8) 1028 (48.0) 0.006 1627 (54.7) <0.001
MMSE, med (IQR) 21 (29) 22 (30) <0.001 21 (28) <0.001
Type of dementia
AD, n (%) 582 (19.5) 462 (21.6) 0.077 555 (18.7) 0.010
MD, n (%) 662 (22.2) 433 (20.2) 0.081 661 (22.2) 0.083
VaD, n (%) 801 (26.9) 630 (29.4) 0.049 811 (27.3) 0.093
OD, n (%) 933 (31.3) 618 (28.8) 0.056 948 (31.9) 0.020
Living alone, n (%) 1309 (48.4) 793 (39.4) <0.001 1499 (58.2) <0.001
Living in an institution, n (%) 458 (15.4) 155 (7.2%) <0.001 565 (19.1) <0.001
AF, atrial fibrillation, n (%), number of patients in each category and percentage relative to the whole cohort; SD, standard deviation; IQR,
interquartile range, MMSE, Mini-Mental State Examination, AD, Alzheimer’s dementia; VaD, vascular dementia; MD, mixed AD and VaD;
OD, other dementia diagnoses including Parkinson’s disease with dementia, dementia with Lewy bodies, frontotemporal dementia, and
unspecified dementia. Missing values: Age at diagnosis, dementia type and sex had no missing values. MMSE had 422 (5.2%) missing
values, living alone 803 (9.9%), living in institution 27 (0.3%).
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Table 2
Comorbidities in patients with atrial fibrillation before and after dementia diagnosis
Atrial fibrillation (N= 8,096) No treatment Warfarin p-value for Antiplatelets p-value
(n= 2,978; 37%) (n= 2,143; 27%) dif. to no (n= 2,975; 37%) for dif. to
treatment warfarin
Number of drugs, med (IQR) 5.0 (23) 6.0 (21) <0.001 6.0 (23) <0.001
Comorbidities at dementia diagnosis
Diabetes mellitus, n (%) 520 (17.5) 460 (21.5) <0.001 596 (20.0) 0.212
Hypertension, n (%) 1817 (61.0) 1400 (65.3) 0.002 1908 (64.1) 0.378
Liver disease, n (%) 50 (1.7) 20 (0.9) 0.023 34 (1.1) 0.469
Kidney disease, n (%) 334 (11.2) 179 (8.4) 0.001 327 (11.0) 0.002
Heart failure, n (%) 1062 (35.7) 841 (39.2) 0.009 1100 (37.0) 0.099
Pacemaker, n (%) 388 (13) 351 (16.4) 0.001 291 (9.8) <0.001
Previous ischemic heart disease, n (%) 985 (33.1) 750 (35.0) 0.152 1202 (40.4) <0.001
Previous all stroke, n (%) 659 (22.4) 503 (23.5) 0.258 704 (23.7) 0.873
Previous ischemic stroke, n (%) 494 (16.6) 432 (20.2) 0.001 533 (17.9) 0.043
Previous nontraumatic intracranial hemorrhage, n (%) 116 (3.9) 23 (1.1) <0.001 97 (3.3) <0.001
Previous traumatic intracranial hemorrhage, n (%) 81 (2.7) 22 (1.0) <0.001 65 (2.2) 0.002
Previous any hemorrhage, n (%) 571 (19.2) 284 (13.3) <0.001 467 (15.7) 0.015
Outcomes after dementia diagnosis
All stroke, n (%) 243 (8.2) 176 (8.2) 0.946 338 (11.4) <0.001
Ischemic stroke, n (%) 180 (6.0) 111 (5.2) 0.187 260 (8.7) <0.001
Nontraumatic intracranial hemorrhage, n (%) 40 (1.3) 40 (1.9) 0.136 49 (1.6) 0.553
Traumatic intracranial hemorrhage, n (%) 32 (1.1) 23 (1.1) 0.996 35 (1.2) 0.731
Any hemorrhage, n (%) 199 (6.7) 160 (7.5) 0.278 205 (6.9) 0.430
Death, n (%) 1105 (37.1) 600 (28.0) <0.001 1389 (46.7) <0.001
AF, atrial fibrillation, N (%), number of patients in each category and percentage relative to the whole cohort, IQR, interquartile range. For
number of drugs there were 339 (4.2%) missing.
the antiplatelet (p= 0.187) and 260 (8.7%) in the
no-treatment group (p< 0.001). ICH appeared in
1.9% of patients on warfarin compared to 1.6% on
antiplatelets (p= 0.553) and 1.3% with no treatment
(p= 0.136). There were no significant differences in
the rates of any-cause hemorrhage. During follow-
up, 3,094 deaths occurred: in the warfarin group
600 (28%) died, compared to 1,389 (46.7%) in the
antiplatelet, and 1,105 (37.1%) in the no-treatment
groups (p< 0.001). Comorbidities of the patients are
listed on Table 2.
Survival analyses
Compared to no treatment, in the fully-adjusted
model, warfarin was associated with a lower risk for
IS (HR 0.76, 95% CI 0.59–0.98), while antiplatelets
were associated with increased risk (HR 1.25, 95% CI
1.01–1.54). In sex-stratified analyses, warfarin was
associated with reduced risk of IS compared to no
treatment in women (HR 0.65, 95% CI 0.45–0.94),
with non-significant results in men (HR 0.89, 95% CI
0.62–1.27).
There were no significant associations for ICH in
patients on warfarin compared to no treatment (HR
1.47, 95% CI 0.91–2.37) or antiplatelets (HR 1.16,
95% CI 0.75–1.80). No significant difference for ICH
was found between antiplatelets and no treatment
(HR 1.29, 95% CI 0.81–2.04).
Similarly, there was no significant association
for any-cause hemorrhage between warfarin or
antiplatelets compared to no treatment (warfarin HR
1.08, 95% CI 0.87–1.35; antiplatelets HR 0.85, 95%
CI 0.68–1.04). However, compared to antiplatelets
there was a higher risk of hemorrhage with warfarin
(HR 1.28, 95% CI 1.03–1.59). Stratifying by sex,
the association between any-cause hemorrhage and
warfarin was shown only in men (HR 1.43, 95% CI
1.05–1.96). In men, there was an association with
lower risk for any-cause hemorrhage in patients on
antiplatelets compared to no treatment (HR 0.71, 95%
CI 0.52–0.97).
Treatment with warfarin or antiplatelets was asso-
ciated with lower HR for death compared to no
treatment (warfarin: HR 0.84, 95% CI 0.59–0.98,
antiplatelets: HR 0.91, 95% CI 0.83–0.99). However,
in propensity score adjusted models, treatment with
antiplatelets was not associated with lower risk for
death compared to no treatment (HR 0.99, 95% CI
0.90–1.08) (Supplementary Table 1). In patients with-
out previous IS, there was an association between
warfarin and lower HR for death compared to no-
treatment (HR 0.84, 95% CI 0.74–0.95). In patients
without previous hemorrhage there was lower HR
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Table 3
Hazard ratios (HR) of ischemic stroke, nontraumatic intracranial hemorrhage, any hemorrhage and death compared to no treatment
HR for ischemic HR for nontraumatic HR for any HR for death
stroke (95% CI) intracranial hemorrhage (95% CI)
hemorrhage (95% CI) (95% CI)
No treatment Ref. Ref. Ref. Ref.
Warfarin 0.76 (0.59–0.98)* 1.47 (0.91–2.37) 1.08 (0.87–1.35) 0.84 (0.59–0.98)**
Antiplatelets 1.25 (1.01–1.54)* 1.29 (0.81–2.04) 0.84 (0.68–1.04) 0.91 (0.83–0.99)*
Hazard ratios (HR) and 95% confidence intervals (CI) for the association of treatment with warfarin or antiplatelets (aspirin or clopido-
grel) and risk of ischemic or nontraumatic intracranial hemorrhage and death after dementia diagnosis, as obtained from Cox Hazards
regression models. Adjusted for age, sex, number of drugs, Mini-Mental State Examination, dementia type (Alzheimer’s dementia
versus other), nursing home placement, previous diabetes, hypertension, heart failure, ischemic stroke, any-cause hemorrhage, liver
and kidney disease.
Table 4
Hazard ratios of ischemic stroke, nontraumatic intracranial hemorrhage, any hemorrhage and death compared to antiplatelet treatment
HR for ischemic HR for nontraumatic HR for any HR for death
stroke (95% CI) intracranial hemorrhage (95% CI)
hemorrhage (95% CI) (95% CI)
Antiplatelets Ref. Ref. Ref. Ref.
Warfarin 0.62 (0.49–0.78)*** 1.16 (0.75–1.80) 1.28 (1.03–1.59)* 0.93 (0.84–1.03)
No treatment 0.80 (0.65–0.99)* 0.81 (0.51–1.28) 1.19 (0.96–1.47) 1.12 (1.02–1.23)*
Same analyses as presented in Table 3, but with antiplatelets as reference category. Adjusted for age, sex, number of drugs, Mini-Mental
State Examination, dementia type (Alzheimer’s dementia versus other), nursing home placement, previous diabetes, hypertension, heart
failure, ischemic stroke, any-cause hemorrhage, liver and kidney disease.
for death in patients with warfarin compared to no
treatment (HR 0.84, 95% CI 0.75–0.95), which was
also present in the antiplatelet group (HR 0.90, 95%
CI 0.81–1.00). Hazard ratio analysis is presented in
Tables 3 and 4.
DISCUSSION
In this Swedish cohort of dementia patients with
AF, warfarin treatment at the time of dementia diag-
nosis was associated with lower risk of IS than
antiplatelets or no treatment. This is in line with the
protective effect of warfarin for stroke in patients
with AF observed in the general [6–8, 21] and older
[22] populations, as well as in patients with recently
diagnosed dementia [23].
In our study, rates of IS were in the range from
5.2% in the warfarin group, 6.0% in the antiplatelet
to 8.7% in the no-treatment group, which would cor-
respond to annual rates 3% in warfarin group, 3.4% in
the antiplatelet, and 5.0% in the no-treatment group,
which is relatively low compared to other studies. The
average IS rate in the general AF population (mean
age 71 years) was 4.6% for warfarin for secondary
prevention and 1.8% per year for primary prevention
in previous studies [6]. With antiplatelet treatment
this rises to 10.5% for secondary and 3.9% for pri-
mary prevention compared to 13.0% per year for
secondary prevention and 4.1% per year for primary
prevention in untreated participants [6]. However, in
patients with dementia there may be a general under-
diagnosis of stroke, if cognitive symptoms obscure
new neurological focality or if patients in palliative
stages are not sent to hospital. This could explain
lower annual rates of stroke found in our study.
The most common adverse effects of warfarin and
antiplateletsarehemorrhages, andmost studiesonpri-
mary and secondary stroke prevention in AF show
increase in absolute risk for ICH and major bleeding
[6–8, 21]. In our study the crude rates of hemor-
rhagic stroke and any-cause hemorrhage did not differ
between the treatment groups, although in adjusted
survival analyses an association was found between
warfarin and risk of any-cause hemorrhage com-
pared to antiplatelet treatment. In a previous study
on an older population with AF, no significant dif-
ferences were found in the rate of ICH or major
hemorrhage with warfarin compared to aspirin [22],
and another smaller study among octogenarians did
not detect major bleedings in any of the treatment
groups [24]. Lower incidence of ICH with warfarin
in these studies can be partly explained by patient
selection: in the Birmingham Atrial Fibrillation Treat-
ment of the Aged Study patients for whom warfarin
was clearly indicated were excluded because of eth-
ical reasons, so participation in study was restricted
to patients with lower risk for stroke, for whom there
was clinical uncertainty which of the two treatments
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should be used [22]. Additionally, pooled data from
five randomized trials indicated almost no increase
in frequency of major bleeding with antithrombotic
treatment (1.3% for the warfarin group, 1.0% for the
aspirin group, and 1.0% for the control group) [25]. A
meta-analysis on twenty-nine randomized controlled
trials investigating long-term antithrombotic therapy
in patients with AF found that the risk for ICH dou-
bled with warfarin compared to aspirin, although
the absolute risk increase was small (0.2%/year) [6].
There was a similar absolute rate increase for major
extracranial bleeding events for warfarin versus con-
trol (3%), warfarin versus aspirin (2%), and for aspirin
versus control (2%) [6]. These studies were conducted
among older patients, with a mean age of 71 years.
In the European/Australasian Stroke Prevention in
Reversible Ischaemia Trial, which investigated sec-
ondary prevention of stroke and compared OAC with
a target international normalized ratio (INR) between
2.0–3.0 with aspirin treatment, the annual incidence
of ICH was between 0.31–1.21% in anticoagulated
patients [26]. The incidence of ICH for aspirin was
0.39% per year [27]. This compares with the inci-
dence of ICH in the present study which ranges from
1.3 to 1.9% over a follow-up which is approximately
1.7 years, which translates approximately into 1.12%
ICH per year in dementia patients treated with war-
farin. Our findings suggest that the hemorrhagic risk
in patients with dementia is similar to what has pre-
viously been reported among older patients. When
evaluating warfarin prescription, the risk of IS must
be weighed against the risk of ICH and other hem-
orrhagic complications. In our data, the absolute rate
of IS during follow-up was approximately 3–5 times
higher than that for ICH, which is comparable to other
studies [28].
In our cohort, there was an association with
increased risk for ICH with advanced age, previ-
ous hypertension, and previous hemorrhage. Previous
studies that investigated use of warfarin for preven-
tion of thromboembolism in AF showed higher rate
of bleeding in the older age groups, but also higher
rate of IS indicating a greater need for anticoagulation
[29, 30]. However, in previous studies older patients
(aged > 75) were significantly underrepresented [9].
In many of these studies, it was also shown that occur-
rence of ICH is mainly related to the intensity of
anticoagulant therapy. For example, in the Stroke Pre-
vention in Reversible Ischaemia Trial, the incidence
of major hemorrhages in patients with INR between
2.0–3.0 was two thirds lower than in those with INR
3.0–4.5 [27].
For this reason, maintaining an INR within the
target range is critical to treatment success and non-
adherence or drug-drug interactions that threaten this
balance are sufficient reasons to withhold or with-
draw treatment [13]. Dementia has been shown to be
one of the main risk factors for nonadherence to OAC
therapy [31]. In a recent study on cognitive function
and adherence to anticoagulation treatment, 46.8%
of patients with cognitive disorders had low levels of
medication adherence [32]. However, another study
in patients with AF who received a new diagnosis
of dementia has shown good anticoagulation con-
trol, as measured according to time in therapeutic
range (TTR) (mean TTR before dementia diagno-
sis was 58.8± 22.6% for all patients on warfarin,
62.0± 18.4% for those who remained on warfarin
after diagnosis with dementia and 65.8± 18.9% for
those without dementia) [23].
In our study, a high proportion of patients with
dementia and AF were living alone (40% with war-
farin treatment, 48% with antiplatelets, and 58% with
no treatment). Monitoring and care of patients with
AF in Sweden is well organized, with many patients
receiving help with medication administration and
INR control in their own homes—and this must be
kept in mind before generalizing the findings of this
study to other countries [33]. Cardiovascular medi-
cation use in patients with dementia shows regional
variations, which must be taken into account when
extrapolating these results to other cohorts [34]. War-
farin and antiplatelet treatment were associated with
lower risk for death compared to no treatment in
the present study. Compared to antiplatelet treatment,
there was a non-significant trend toward lower risk for
death with warfarin. Some previous studies reported
better survival with warfarin compared to placebo
[6, 35], while others comparing warfarin to anti-
platelet therapy found no significant differences in
survival [8, 21]. Pooled data from twenty-nine ran-
domized controlled trials showed lower all-cause
mortality for warfarin versus controls (RRR, rela-
tive risk reduction, 26%), for warfarin versus aspirin
(RRR, 9%), and for aspirin versus controls (RRR,
14%) [6]. Warfarin was associated with lower mor-
tality (HR 0.72, 95%CI 0.60–0.87, p< 0.001) also in
patients with dementia [23]. This effect has to be
interpreted with caution, because there can be bias
occurring if patients with a lower life expectancy
were not treated at all. In our study, when stratify-
ing by sex, treatment with warfarin compared to no
treatment was associated with reduced risk of IS in
women, while results in men were not significant.
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This finding is in line with previous studies showing
that women with AF have an increased risk of IS, [36]
and would therefore benefit more from warfarin.
The current study has several limitations. The data
has been obtained from registries, and important fac-
tors affecting treatment decisions, such as possible
contraindications for warfarin treatment, patient pref-
erences, compliance, INR at the time of occurrence
of the adverse events and TTR, were not available.
Patients were classified according to their treatment
status at the time of dementia diagnosis. Therefore,
patients could have changed treatment groups in the
course of follow-up. These changes could possibly
have led to the underestimation of the protective effect
of warfarin on stroke risk, but also an underestima-
tion of the hemorrhagic complications, if as expected,
patients are taken off warfarin as cognitive deteri-
oration progresses. The Patient Registry covers all
inhospital and specialist clinic diagnosis: since acute
stroke is primarily a hospital diagnosis, the coverage
for this outcome should be good, although diagnostic
precision is always a concern. The estimated cover-
age of SveDem is approximately 35% [15]. There
are no studies on the differences between demen-
tia patients in SveDem and non-registered patients,
however, we can assume that patients included in
the quality register are in general healthier [37]. This
may bias the generalizability of the results towards a
healthier group of patients and may lead to an under-
estimation of the comorbidities and their influence on
risk of stroke and death.
This is an observational study and treatment was
not randomly allocated, so there may be important
differences between patients in the different treatment
groups. Antithrombotic treatment is often withheld
in patients with poor survival prognosis. The data to
assess frailty index and information on number of
falls was not available and controlling for comorbidi-
ties and cognitive level may not adequately account
for this. The low incidence of ICH and any hemor-
rhage in the warfarin group in this study could be
partly explained because possible contraindications
for warfarin were taken into consideration when pre-
scribing the medication, which could have eliminated
differences between the treatment groups. The excess
risk for IS found with antiplatelets could indicate that
this group of patients were prescribed antiplatelets for
reasons other than AF (confounding by indication),
which would imply a higher risk for atherothrom-
botic stroke, in addition to the embolic stroke
risk. Confounding by indication could also explain
the lower risk of ICH in men taking antiplatelets,
compared to no treatment. For outcomes, we included
only IS without peripheral emboli, which can be also
caused by AF, although much rarer and often clini-
cally silent [38]. This study does not include the new
generation of oral anticoagulants because their use
has only recently increased in Sweden and the num-
ber of patients and follow-up time during the study
period was limited.
One of the strengths of this study is the inclu-
sion of a uniquely large sample of patients with
dementia from a nationwide register. Moreover, the
diagnoses of AF, comorbidities and information on
drugs were obtained from Swedish health registers
that have a complete national coverage. The diag-
nosis of AF and comorbidities were obtained from
Swedish National Patient register, which has high
overall diagnostic validity (85–95%) [18]. Monitor-
ing of the data in SveDem is performed by random
cross-checks of histories and entries [15] and around
5% of dementia diagnoses change during the first year
of follow-up [16]. Despite the irruption of NOACs,
warfarin remains the most prescribed anticoagulant
worldwide and studies examining the risk-benefits of
warfarin treatment among patients with dementia are
still clinically relevant. Since randomized studies in
this subject are ethically and methodologically chal-
lenging, cohort studies represent the next-best option
in answering these questions. The low percentage
of treated patients is also a surprising finding, and
implies that great gains can be made in stroke pre-
vention in patients with dementia and AF in Sweden
by extending treatment to all appropriate cases. How-
ever, as treatment is extended to borderline cases,
the risk of complications would increase and future
cohort studies should monitor trends in treatment,
complications, and the effects of the introduction of
NOACs among patients with dementia in Sweden.
Conclusions
In this nationwide cohort study of patients with
dementia and AF, the use of warfarin compared
to no treatment was associated with lower risk of
ischemic stroke and mortality. The use of warfarin
compared to antiplatelets was associated with lower
risk of ischemic stroke. There was no significant
increase in hemorrhagic complications with war-
farin compared to no treatment, and no differences
in nontraumatic ICH. A higher risk of any-cause
hemorrhage was shown with warfarin compared to
antiplatelet treatment but the absolute risk was small.
The crude rates of IS were 3–5 times higher than the
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rates of ICH, which is in line with previous stud-
ies. This supports the use of warfarin in appropriate
cases in patients with dementia, and indicates that
current patient selection and warfarin control in Swe-
den have succeeded in avoiding excess hemorrhagic
complications.
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Povzetek 
Uvod: Bolniki z demenco naj bi imeli višje tveganje za smrt zaradi možganske kapi. Namen 
članka je bil opisati značilnosti švedskih bolnikov z demenco, ki so umrli zaradi ishemične 
možganske kapi. 
Metode: Raziskava je longitudinalna kohortna študija prospektivno zbranih podatkov o 
bolnikih iz Švedskega nacionalnega registra za demence (SveDem). Podatki o sočasnih 
boleznih, zdravljenju in smrti so bili pridobljeni iz nacionalnih švedskih zdravstvenih registrov. 
Možganska kap je bila opredeljena za vzrok smrti, če je bila na mrliškem listu omenjena kot 
glavni ali posredni vzrok smrti in če je bil bolnik predhodno vpisan v Švedski nacionalni 
register za možganske kapi (Riksstroke). Primerjali smo osnovne značilnosti bolnikov, ki so 
umrli zaradi ishemične možganske kapi in bili v zadnjem letu pred smrtjo vpisani v Riksstroke; 
bolnikov, ki so umrli zaradi ishemične možganske kapi in niso bili vpisani v Riksstroke ter 
bolnikov, ki so umrli zaradi drugih vzrokov. 
Rezultati: Med 49.823 bolniki, ki so prejeli diagnozo demence v obdobju 2007–2014 na 
primarni ravni ali specialističnih klinikah, jih je 14170 (28.4%) umrlo do vključno leta 2014. 
Med njimi je 1180 (8.3%) bolnikov imelo navedeno kot vzrok smrti na mrliškem listu 
ishemično možgansko kap. Od teh jih je bilo le 459 (38.9%) predhodno vpisanih v švedski 
nacionalni register za možganske kapi. Pri bolnikih, ki so umrli zaradi ishemične možganske 
kapi, je bila najpogostejša vrsta demence vaskularna demenca, medtem ko so bili bolniki, ki so 
umrli zaradi drugih vzrokov smrti, najpogosteje diagnosticirani z Alzheimerjevo demenco. 
Bolniki, ki so umrli zaradi ishemične možganske kapi in so bili vpisani v Riksstroke, so imeli 
višje vrednosti na KPSS-ju v času diagnoze demence, v primerjavi z bolniki v drugih skupinah. 
Bolniki, ki so umrli zaradi ishemične možganske kapi, so prejemali več zdravil za srčnožilne 
bolezni. Glede uporabe antipsihotikov, antidepresivov, inhibitorjev acetilholinesteraze, 
memantina, anksiolitikov in hipnotikov, se bolniki, ki so umrli zaradi ishemične možganske 
kapi, niso statistično pomembno razlikovali od bolnikov, ki so umrli zaradi drugih vzrokov 
smrti. 
Zaključki: Več kot polovica bolnikov, pri katerih je bil vzrok smrti, zabeležen na mrliškem 
listu, ishemična možganska kap, ni bila vpisanih v švedski nacionalni register za možganske 
kapi. To sproža vprašanje o točnosti diagnoz možganske kapi na mrliških listih, predvsem pri 
umrlih izven bolnišnic. 
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Abstract: Introduction: Patients with dementia may be at a higher risk for death from stroke. We aimed 
to describe characteristics of dementia patients that died from ischemic stroke (IS) in Sweden.  
Methods: A retrospective longitudinal analysis of prospectively collected data of patients registered into 
the Swedish Dementia Registry was conducted. Data on causes of death, drugs and comorbidities were 
acquired from the Swedish nationwide health registers. Deaths were attributed to stroke if the death cer-
tificate contained stroke as a cause of death and the patient had a stroke registered in Riksstroke, the 
Swedish Stroke Register, in the year preceding death. Demographic data at the time of dementia diagno-
sis was compared between patients dying from IS and registered in Riksstroke, patients dying from IS 
without being registered in Riksstroke and those dying from other causes. 
Results: Out of 49823 patients diagnosed with dementia between 2007 and 2014 in primary care or spe-
cialist clinics, 14170 (28.4%) had died by the end of 2014. Of these 1180 (8.3%) had IS in their death 
certificate, of which 459 (38.9%) had been registered in Riksstroke. In patients who died of IS the most 
common type of dementia was vascular dementia while those died from other causes were most often 
diagnosed with Alzheimer’s dementia (AD). Patients who died from IS and were registered in Riks-
stroke had higher MMSE score compared to other groups. Patients who died from IS took more cardio-
vascular medications. There were no differences in the use of antipsychotics, antidepressants, acetylcho-
linesterase inhibitors, memantine, anxiolytics, or hypnotics between the groups.  
Conclusions: There was a relatively high number of patients who died from IS as shown in their death 
certificate but had not been registered in Riksstroke in the year before death. This creates concerns on 
the accuracy of death certificate stroke diagnoses, particularly for deaths taking place outside hospitals.  
Keywords: Swedish dementia registry, SveDem, Swedish Stroke Registry, riksstroke, dementia, ischemic stroke, death certifi-
cate. 
1. INTRODUCTION 
Mortality due to stroke has been declining over the past 
decades, most likely due to better management of vascular 
risk factors [1]. However, patients with dementia may be at a 
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higher risk of dying from stroke [2]. Moreover, patients with 
dementia receive less intensive health care and they may not 
be appropriately managed for their cardiovascular comorbid-
ities [3-5].  
In the general population, stroke is the leading cause of 
death among older women and the second most frequent 
cause of death in Sweden overall [6]. In patients with de-
mentia, the most common causes of death are bronchopneu-
monia and cardiovascular disease while death from neoplas-
1875-5828/18 $58.00+.00 © 2018 Bentham Science Publishers 
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tic diseases is less common compared to the general older 
population [2, 7-10]. 
The severity of dementia may also influence the cause of 
death. While bronchopneumonia occurred more often in se-
verely affected Alzheimer's disease (AD) patients, heart dis-
ease, stroke and other common causes of death predominated 
in less cognitively impaired patients [11]. In a recent study 
from SveDem stroke was a cause of death in 18.6% [10]. 
Dementia type is associated with cause of death - cere-
brovascular diseases (CVD) are a significantly more com-
mon cause of death in vascular dementia [10, 12] patients 
compared to AD patients (33.3% vs. 9.3 %) [10, 13]. How-
ever, most previous studies focused exclusively on AD pa-
tients and less information exists on stroke as a cause of 
death in other dementia types. 
Death certificates are widely used in ascertainment of 
cause of death [14, 15]. Although their quality has been 
questioned, particularly in older individuals [15], a recent 
study with Swedish death certificates found an agreement of 
87-88% for cardiovascular causes of death at the 3-digit level 
of the ICD-10 [16]. Swedish quality registers have a long 
tradition for improving quality of care and are often used in 
research. In a previous study from the Swedish Dementia 
Registry (SveDem), we examined the causes of death from 
death certificates according to dementia type and underlying 
demographic factors [10]. Now, we propose a study focusing 
on ischemic stroke (IS), with the aim to describe the charac-
teristics of patients with dementia dying from stroke and to 
determine what proportion of patients with a stroke in their 
death certificate had been diagnosed with stroke before 
death. A cross-reference with the Swedish Stroke Register 
[17] was performed to determine whether individuals re-
ceived a stroke diagnosis before the terminal event, in an 
effort to increase the reliability of the death certificate diag-
noses. Lastly, we aimed to establish whether the place of 
death contributed to missing clinical stroke diagnoses in pa-
tients dying from stroke according to their death certificates. 
2. MATERIALS AND METHODS 
A retrospective analysis of prospectively collected data 
of patients registered in the quality Swedish Dementia Regis-
try (SveDem) was conducted. Information about the causes 
of death was acquired from the Swedish Death Register, 
about comorbidities from the Swedish Patient Register and 
about drugs from the Swedish Prescribed Drugs Register. 
Patients and their relatives were informed of the entry into 
SveDem and could decline participation or have their data 
removed at any time. Data were de-identified before analy-
sis. This study complies with the Declaration of Helsinki and 
was approved by the regional ethical review board in Stock-
holm, Sweden (dnr 2015/743-31/4). 
2.1. Source of Data 
The Swedish Dementia Registry (SveDem) was estab-
lished in May 2007, with the aim to monitor the care of pa-
tients with dementia in Sweden, as previously described in 
detail [18]. Patients with dementia are registered at the time 
of their dementia diagnosis by physicians in memory clinics 
or primary care units. Diagnoses were made according to the 
International Classification of Diseases version 10 (ICD-10) 
criteria, [19] with specific criteria used for the different de-
mentia types. The following dementia disorders are included 
in SveDem and were considered for this study: Alzheimer's 
dementia (AD), vascular dementia [12], mixed AD and VD 
(mixed), dementia with Lewy bodies (DLB), frontotemporal 
dementia (FTD), Parkinson's disease dementia (PDD) and 
unspecified dementia (UD). Information on age, sex, Mini-
Mental State Examination (MMSE) score, use of medication 
and living conditions are recorded. In the present study, we 
use data of patients that were registered between 2007 and 
2014. 
Data on death were obtained from death certificates col-
lected in the Swedish Death Register until December 2014. 
IS was included as the cause of death if it was mentioned 
either as the main or contributory cause (ICD-10 code I63). 
All other causes of death were included in the variable “dead 
from other causes”. The Swedish Stroke Registry covers all 
Swedish hospitals involved in acute stroke with a coverage 
>90% for IS events [17] and was used to ascertain stroke 
diagnoses [20]. Stroke events occurring between 2007 and 
2014 were included. Deaths were attributed to stroke if the 
death certificate contained stroke as the cause of death and 
the patient had a stroke registered in Riksstroke within 1 year 
prior to death. The place of death was either hospital, nursing 
home or at home.  
Information on comorbidities was obtained from the 
Swedish Patient Registry that covers all hospital and special-
ist care in Sweden [21]. One main diagnosis and up to 21 
additional diagnoses are registered with ICD 10 codes. In the 
present study, we considered a comorbidity present if the 
code appeared at least once as the main or additional diagno-
sis from 1998 until the end of 2014. We used the following 
codes for comorbidities: diabetes mellitus (E10-E13), arterial 
hypertension (I10-I15), anemia (D50 and D62), liver dis-
eases (K70-77), kidney diseases (N10-19), heart failure 
(I50), atrial fibrillation (I48), previous femur fracture (S72), 
previous stroke (I64, I63, I60-I62). 
Information on drug use was obtained from the Pre-
scribed Drugs Registry which contains information on all 
dispensed prescriptions since July 2005 at Swedish pharma-
cies to the entire Swedish population [22]. Drugs are coded 
according to the Anatomical Therapeutic Chemical (ATC) 
Classification system. In the present study, we analyzed 
drugs dispensed at the time of dementia diagnoses and up to 
3 years prior to this date, using the following codes: 
antidiabetic drugs (A10), antithrombotic agents (B01), diu-
retics (C03), beta blocking agents (C07), calcium-channel 
blockers (C08), agents acting on the renin-angiotensin sys-
tem (C09), lipid-modifying agents (C10), antipsychotics 
(N05A), antidepressants (N06A), cholinesterase inhibitors 
(ChEIs) (N06DA), memantine (N06DX01), anxiolytics 
(N05B), hypnotics and sedatives (N05C). The use of sleep-
ing aids was obtained from SveDem since ATC codes do not 
always reveal the intention of the prescription. Further, we 
consider the total number of medication at the time of de-
mentia diagnosis as a proxy for overall co-morbidity. 
2.2. Statistical Analyses 
Data is described as means ± standard deviation (SD), 
median and interquartile range (IQR) or frequency (number-
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n and percentage-%), where appropriate. Baseline character-
istics of the patients at the time of dementia diagnosis were 
compared between patients dying from IS and registered in 
Riksstroke, patients dying from IS without being registered 
in Riksstroke and those dying from other causes using chi-
square test or T-test, as appropriate. Age was compared us-
ing ANOVA with the Welch test because of non-
homogenous variances and the total number of drugs using 
the Kruskal-Wallis test. Logistic regression was used to as-
sess the association of place of death (hospital, nursing home 
or at home) with IS in the death certificate and having a 
Riksstroke registration. The final models were adjusted for 
age, sex, number of medication, MMSE, dementia type, pre-
vious diagnosis of diabetes, hypertension, heart failure, atrial 
fibrillation, stroke, anemia, hip fracture, liver diseases and 
kidney diseases. Adjusted odds ratios (ORs) with 95% con-
fidence intervals (CIs) are presented. 
Two-tailed P < 0.05 was considered to be statistically 
significant in all analytical procedures. Data were analysed 
using the Statistical Package for the Social Sciences software 
version 22 (IBM Corporation, Armonk, NY, USA). 
3. RESULTS 
Out of 49823 patients diagnosed with dementia between 
2007 and 2014 in primary care or specialist clinics, 14170 
(28.4%) had died by the end of 2014. Of these, 1180 (8.3%) 
had IS mentioned in their death certificate, of which 459 
(38.9%) had also been registered in Riksstroke for a stroke 
event in the year preceding death. Characteristics of the co-
hort are presented in Table 1. Of patients who died of IS, 
there were additionally 153 patients who had a Riksstroke 
registration more than a year preceding death, totaling 612 
patients with a confirmed IS or 52% of those with IS men-
tioned on their death certificates. Characteristics of this co-
hort are presented in Supplemental Table 1.  
Among patients who died of IS, the most common type 
of dementia was VD, while those dead from other causes 
were most often diagnosed with AD. Patients who died from 
IS and were registered in Riksstroke had higher MMSE 
score compared to other groups (21.0 vs. 20.0 vs. 20.0; 
p<0.001). 
56.0% of patients died from IS and registered in 
Riksstroke died in hospital compared to 16.8% patients who 
died from IS without being registered in Riksstroke, and 
25.1% who died from other causes. Patients who died from 
IS were slightly older when registered in SveDem, but in all 
groups patients died with a mean age of 84 years.  
Patients who died from IS took more medications at the 
time of dementia diagnosis, when compared to patients who 
died from other causes (6.0 vs. 5.0; p<0.001). Specifically, 
they were prescribed more cardiovascular drugs, such as 
antithrombotic agents, beta-blockers, agents acting on the 
renin-angiotensin system, lipid-modifying agents and an-
tidiabetics. There were no statistically significant differences 
in the use of antipsychotics, antidepressants, ChEIs, meman-
tine, anxiolytics, or hypnotics between the groups. Fig. (1) 
shows medication use at the time of dementia diagnosis in 
patients who died from IS and those who died from other 
causes.  
Dying in a hospital was associated with increased odds of 
having a stroke in the death certificate and being registered 
in Riksstroke (Table 3). Compared to patients dying in a 
hospital, those dying in a nursing home had lower odds of 
having IS in their death certificates (OR 0.80, 95% CI 0.69-
0.92) and, among those dying from IS, nursing home resi-
dents were less likely to present a Riksstroke registration 
within one year of death (OR 0.17, 95% CI 0.12-0.22). 
4. DISCUSSION 
There were 8% of patients with dementia in our study 
who died from IS, which is slightly higher than the 6% that 
die from IS in the general population [23]. Some studies 
evaluated stroke as a cause of death in dementia patients [2, 
7, 8, 11, 13] providing conflicting results. Some showed that 
death because of CVD was more common in dementia pa-
tients than in the general population [2] while others did not 
demonstrate a difference, [8] or showed the opposite results 
[7]. Death from CVD accounted for around 4-13% of all 
deaths in patients with dementia in different studies [2, 7]. 
In our cohort, only one-third of all patients who died of 
IS had been registered in Riksstroke for a stroke event in the 
year preceding death. There are a few possible explanations 
for this low number of registrations in Riksstroke. First, it is 
estimated that around 10% of strokes may be missed by 
Riksstroke (90% coverage) [17]. Further, some patients with 
strokes may survive more than one year from the stroke 
event and would have been excluded from this study: in 
these cases, however, it may be hard to attribute the death to 
stroke. Therefore we performed a secondary analysis includ-
ing all patients with previous Riksstroke registration irre-
spective of the time between stroke and death. This increased 
the percentage of patients with an established stroke diagno-
sis to 52% but did not change the findings of previous analy-
sis (Supplemental Table 1, 2, 3). In a previous study examin-
ing mortality after IS, the highest mortality rate occurred in 
the first 3 months after IS but remained elevated even among 
patients who survived 2 years [24] . In the first month after 
IS, deaths were caused primarily by neurologic complica-
tions of brain ischemia, while later deaths were mostly asso-
ciated with cardiac and pulmonary events [24]. Similarly, 
another study examining long-term survival after stroke 
found that stroke was associated with an almost 5-fold in-
crease in risk for death between one month and one year 
after the first stroke and a 2-fold increase after 1 year com-
pared with the general population. In this study, almost half 
of the patients died one year after the stroke [25]. In another 
study that examined early and long-term causes of death 
after IS, stroke caused early deaths in 57% and only 14% 
long-term deaths [26]. 
Another important point is the accuracy of death certifi-
cate diagnosis. Different definitions of stroke as a cause of 
death in literature make comparisons between studies chal-
lenging. Beside this, it is well-known among clinicians that 
the diagnosis of stroke in a patient with severe dementia is 
complicated due to impaired communication and cooperation 
at examination [27]. However, generally high error rates 
appeared in death certification - approximately 33-41% of 
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Table 1. Baseline characteristics of patients.  
- Died from Ischemic Stroke 
and Registered in  
Riksstroke1 (N=459) 
Died from Ischemic Stroke, 
not in Riksstroke (N=721) 
Death from Other Causes 
(N=12990) 
P Value 
Place of death 
Hospital 257 (56.0%) 121 (16.8%) 3266 (25.1%) 
Nursing home 182 (39.7%) 522 (72.4%) 8009 (61.7%) 
At Home 6 (1.3%) 30 (4.2%) 705 (5.4%) 
Unknown/blank 4 (3.1%) 48 (6.7%) 1010 (7.8%) 
<0.001† 
 Age at diagnosis, mean ± SD 82.5 ± 6.1  82.3± 6.8 81.9 ± 7.2 0.042‡ 
Age at death, mean ± SD 84.5 ± 6.0 84.6 ± 6.6 84.3 ± 7.0 0.434‡ 
 Female gender, n (%) 274 (59.7%) 404 (56.0%) 7138 (54.9%) <0.118† 
Dementia type, n (%) 
AD 90 (19.6%) 120 (16.6%) 3298 (25.4%) <0.001† 
Mixed 106 (23.1%) 161 (22.3%) 2661 (20.5%) 0.209† 
Vascular 136 (29.6%) 227 (31.5%) 2684(20.7%) <0.001† 
DLB 7 (1.5%) 17 (2.4%) 362 (2.8%) 0.122† 
FTD 3 (0.7%) 5 (0.7%) 188 (1.4%) 0.096† 
PDD 4 (0.9%) 9 (1.2%) 249 (1.9%) 0.124† 
Unspecified 106 (23.1%) 166 (23.0%) 3257 (25.1%) 0.306† 
Other 7 (1.5%) 16 (2.2%) 289 (2.2%) 0.604† 
 MMSE, median (IQR) 21.0 (7) 20.0 (9) 20.0 (9)  <0.001 
0 to 17 155 (33.8%) 305 (42.3%) 5133 (39.5%) 0.013† 
18 to 22 129 (28.1%) 238 (33.0%) 3962 (30.5%) 0.860† 
23 and over 175 (38.1%) 178 (24.7%) 3895 (30.0%) <0.001† 
Total number of drugs, median (IQR) 6.0 (5) 6.0 (6) 5.0 (5) <0.001§ 
Antidiabetics (A10) 62 (13.5%) 107 (14.8%) 1454 (11.2%) 0.004† 
Antithrombotic agents (B01) 270 (58.8%) 412 (57.1%) 5949 (45.8%) <0.001† 
Diuretics (C03) 158 (34.4%) 233 (32.3%) 3859 (29.7%) 0.036† 
Beta blocking agents (C07) 212 (46.2%) 239 (33.1%) 4227 (32.5%) <0.001† 
Calcium-channel blockers (C08) 79 (17.2%) 127 (17.6%) 1981 (15.3%) 0.130† 
Agents acting on the renin-angiotensin 
system (C09) 
165 (35.9%) 231 (32.0%) 3476 (26.8%) <0.001† 
Lipid-modifying agents (C10) 116 (25.3%) 189 (26.2%) 2656 (20.4%) <0.001† 
Antipsychotics (N05A) 30 (6.5%) 63 (8.7%) 1050 (8.1%) 0.388† 
Antidepressants (N06A) 108 (27.1%) 214 (29.7%) 3514 (27.1%) 0.067† 
Cholinesterase inhibitors (N06DA) 157 (35.3%) 222 (32.8%) 4632 (37.2%) 0.053† 
Memantine (N06DX01) 43 (9.7%) 65 (9.7%) 1300 (10.5%) 0.665† 
(Table 1) contd…. 
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- Died from Ischemic Stroke 
and Registered in  
Riksstroke1 (N=459)
Died from Ischemic Stroke, 
not in Riksstroke (N=721) 
Death from Other Causes 
(N=12990) 
P Value 
Cholinesterase inhibitors in patients 
with AD or mixed dementia (N06DA) 
107 (56.0%) 147 (53.8%) 3281 (56.0%) 0.777† 
Anxiolytics (N05B) 55 (12.6%) 115 (17.3%) 1785 (14.7%) 0.081† 
Sleeping aids (N05C) 98 (22.5%) 151 (22.48%) 2497(20.6%) 0.249† 
1Died from ischemic stroke and registered in Riksstroke within the past year. N, number of patients in each category; SD, standard deviation; IQR, interquartile 
range; MMSE, Mini Mental State Examination score. AD, Alzheimer's dementia; mixed, mixed Alzheimer's and Vascular dementia; DLB, Dementia with 
Lewy Bodies; FTD, Frontotemporal dementia; PDD, Parkinson's disease with dementia. P-values obtained from †Chi-Square, ‡ANOVA with Welch test 
because of non-homogenous variances, § Kruskal-Wallis.  
 
Fig. (1). Medication use at the time of dementia diagnosis.  
Antidiabetics (A10), antithrombotic agents (B01), diuretics (C03), beta blocking agents (C07), calcium-channel blockers (C08), agents acting 
on the renin-angiotensin system (C09), lipid-modifying agents (C10), antipsychotics (N05A), antidepressants (N06A), cholinesterase inhibi-
tors (N06DA), memantine (N06DX01), anxiolytics (N05B), sleeping aids (N05C). P values obtained from Chi-Square tests. * P ≤ 0.05; ** P 
≤ 0.01; *** P ≤ 0.001.
Table 2. Comorbidities at dementia diagnosis. 
 - Died from Ischemic 
Stroke and Registered 
in Riksstroke (N=459) 
Died from Ischemic 
Stroke, not in  
Riksstroke (n=721) 
Death from Other 
Causes (N=12990) 
P Value 
Comorbidities at dementia diagnosis   
Diabetes mellitus, n (%)  88 (19.2)  140 (19.4) 2046 (15.8) 0.006 
Arterial hypertension, n (%) 265 (57.7) 371 (51.5) 5705 (43.9) <0.001 
Anemia 34 (7.4) 38 (5.3) 839 (6.5) 0.308 
Liver disease, n (%) 2 (0.3) 4 (0.9) 147 (1.1) 0.088 
Kidney disease, n (%) 43 (9.4) 49 (6.8) 1074 (8.3) 0.250 
Heart failure, n (%) 102 (17.4) 122(16.9) 2264 (17.4) 0.027 
Atrial fibrillation, n (%) 191 (41.6) 193 (26.8) 2859 (22.0) <0.001 
Previous femur fracture, n (%) 50 (10.9) 90 (12.5) 1435 (11.0) 0.485 
Previous stroke, any type n (%) 155 (33.8) 291 (40.4) 2437 (18.8) <0.001 
1Died from ischemic stroke and registered in Riksstroke within the past year. Any type stroke refers to both ischemic and hemorrhagic. P values obtained from 
Chi-Square tests.  
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Table 3. Odds ratios (OR) of having ischemic stroke (IS) and a Riksstroke registration in the death certificate, relative to place of 
death. 
- OR for having IS (95% CI) OR for being Registered in Riksstroke (95% CI) 
Hospital Ref. Ref. 
Nursing home 0.80 (0.69-0.92)*** 0.17 (0.12-0.22)*** 
At Home 0.49 (0.34-0.70)*** 0.09 (0.04-0.23)*** 
Logistic regression was used to assess the association of place of death (hospital, nursing home or at home) with IS in the death certificate and of having a 
Riksstroke registration within the year prior to death. Adjusted for age, sex, number of medication, Mini-Mental State Examination (MMSE), dementia type, 
previous diagnosis of diabetes, hypertension, heart failure, atrial fibrillation, stroke, anemia, hip fracture, liver diseases and kidney diseases. Adjusted odds 
ratios (ORs) with 95% confidence intervals (CIs) are presented. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001. 
incorrectly identified causes of death, with disproportionate 
overrepresentation of cardiovascular events [28]. For exam-
ple, data from the Framingham Heart Study suggests that 
cardiovascular causes of death are overstated in at least 24% 
of cases [29]. There was also concern over the overestima-
tion of stroke diagnosis as the cause of death when there is a 
history of stroke and a lack of an obvious specific cause of 
death [25]. In data from the Framingham Study, a high error 
rate was shown for stroke, including a 40% false negative 
rate in death certificates, which significantly increased with 
increasing age at death and increasing interval from the last 
stroke to death [30]. If death occurred within one month, the 
frequency of false negatives was 7%, but for those who sur-
vived more than one month, it became 59%. Another Swed-
ish study that examined stroke incidence and survival raised 
concern about underestimation of stroke incidence in previ-
ous retrospective studies [31]. They prospectively screened 
for patients with stroke, using multiple overlapping case as-
certainment methods and emphasized the importance of us-
ing recommended criteria for an ideal epidemiological stroke 
study [32]. However, a previous study in Sweden found that 
the main diagnosis from the patient's final hospital discharge 
record differed from the original underlying cause of death 
in the death certificate in more than half of all cases [33]. 
This contradicts other reports on good accuracy of Swedish 
death certificates [16]. 
Having stroke in the death certificate and being regis-
tered in Riksstroke was associated mostly with the place of 
death - dying in a hospital was associated with increased 
odds compared to dying at home or in a nursing home. This 
can be explained because Riksstroke is by definition a 
hospital based register, so patients who have a stroke at nurs-
ing homes or at home and who are not admitted to hospital 
will not be included in the register. Stroke is a clinical diag-
nosis but in order to characterize an event as ischemic or 
hemorrhagic a CT scan of the brain is needed and this can 
only be performed in hospitals, making stroke primarily a 
hospital diagnosis. The current stroke guidelines from the 
Swedish Board of Health and Welfare accept that some very 
frail patients with comorbidities or end-of-life stages may 
not be transferred to the hospital when they suffer a stroke 
[34]. They recommend that this decision be taken in antici-
pation of a potential future stroke event, individualized to a 
particular patient and after discussion with the patient and 
care providers. However, when patients from nursing homes 
have received hospital care they are registered in Riksstroke, 
even if the final place of death is a nursing home. In a recent 
Swedish study, hospitalization proportions for patients with 
acute stroke were around 10% lower than previous estima-
tions. 84% of patients were hospitalized with a median dura-
tion of 7 days, 8% were examined at a hospital but not hospi-
talized, 4% were treated within the primary care organiza-
tion, 1% died before medical examination and 3% had no 
contact with medical services [35]. Another study analysing 
late follow-up after stroke (three months to one year), found 
that 46% of patients died in a nursing home, whereas 37% of 
patients died in a hospital and 10% of patients died at home, 
which is a similar distribution compared to our study [36]. 
4.1. Type of Dementia in Patients who Died from Stroke 
As expected from previous work with causes of death in 
SveDem, we found that most common type of dementia in 
patients who died from stroke was VD [10]. VD is by defini-
tion associated with CVD and therefore patients with VD 
also have higher prevalence of cardiovascular risk factors 
[36].  
The most common type of dementia in patients who died 
from other causes was AD. Some studies showed that pa-
tients with dementia have an increased risk of stroke [37], 
others showed that patients with AD did not have an altered 
risk of ischemic stroke compared to those without dementia, 
whereas patients with VD had an approximately 2-fold in-
creased risk [38]. 
Less is known about stroke in other dementia types. In 
PD, previous studies have shown conflicting results on the 
relationship between IS and PD. To the best of our knowl-
edge there is little data on stroke mortality in PDD, but 
stroke-related mortality was estimated to be 1.5 times higher 
in patients with PD compared to the general population [39]. 
However, in two case-control studies, the risk of stroke was 
lower or not different in PD [40, 41]. In a study on mortality 
in PD, 8% of deaths were from cerebrovascular disease [42]. 
There are also few and conflicting results regarding the 
relationship between IS and DLB, with studies reporting 
both increased [43] and decreased risk [44].  
There was a lower prevalence of cerebrovascular diseases 
in FTD compared to patients with non-FTD dementia 
(12.7% vs. 26.1%) but these differences became non-
significant after adjusting for age [45]. 
To conclude, the data on stroke mortality in different 
types of dementia is still scarce and more research is needed. 
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4.2. Medications in Patients Dead From Stroke 
In our study, we found that patients who died from stroke 
did not differ in the use of antipsychotics, antidepressants, 
ChEIs, memantine, anxiolytics or hypnotics compared to 
patients who died from other causes. This is contrary to pre-
vious studies showing that patients who were taking anx-
iolytic and hypnotic drugs presented with significantly in-
creased risk of mortality and higher prevalence of stroke 
(10% vs.7%; P ≤ 0.001) [46]. In recent years, concern has 
been raised about the increased risk of stroke with the use of 
antipsychotics, both in general population and patients with 
dementia [47, 48]. The risk of death was about 1.2 to 1.6 
times higher compared to the no-treatment group in some 
studies [49, 50]. Because of higher awareness of possible 
side effects, the use of antipsychotics has been restricted in 
patients with dementia. A nationwide study from Denmark 
observed a decrease in the prevalence of antipsychotic use 
among patients with dementia from 31.3% in 2000 to 20.4% 
in 2012 [51]. This was accompanied by a decrease in anx-
iolytics and hypnotics/sedatives, but with an increase in the 
use of antidepressants from 43.3% in 2000 to 53.8% in 2012 
[51]. In comparison, patients in our study used antipsychot-
ics at a lower rate - 6.5% in patients with dementia who died 
from stroke and registered in Riksstroke compared to 8.1% 
who died from other causes [52]. 
4.3. Limitations and Strengths 
This study is strengthened by a large sample of patients 
from different health care setting, reflecting the current clini-
cal practice in Sweden, and the utilization of several nation-
wide registers. The information on causes of death, drugs 
and comorbidities was derived from nationwide health regis-
ters that have a complete coverage in the country. Further-
more, Riksstroke has an excellent coverage in Sweden, con-
taining > 90% of stroke events in the country [53]. Some 
limitations need to be mentioned. In the period examined, 
52% of memory clinics and 48% of primary care units in 
Sweden were affiliated to SveDem and patients in SveDem 
may differ from non-registered patients. It was suggested 
that patients included in a quality register are more likely to 
be men, younger, generally healthier and of a higher socio-
economic status [4]. If this holds for SveDem, it may limit 
the generalizability of our findings to a healthier and 
younger population that has more contact with health care, 
possibly leading to an underestimation of the rate of deaths 
from IS.  
Another weakness of this study is the absence of cogni-
tively normal controls. The ascertainment of stroke as the 
cause of death is obviously a well-founded concern, particu-
larly considering the discrepancies found between stroke as 
the cause of death and stroke registered in Riksstroke.  
This is an observational study, so it is impossible to es-
tablish causation between different medications and out-
comes.  
The validity of the data in SveDem is subject to random 
cross-checks of histories and entries [18] and less than 5% of 
dementia diagnoses change during the first year of follow-up 
[54].  
CONCLUSION 
Mortality data is a cornerstone of epidemiological re-
search and health monitoring. At both the state and national 
level, mortality data compiled from death certificates is used 
to track disease trends, set public health policies, and allocate 
health and research funding [55]. Quality issues may impact 
health care policy. The discrepancy between the registration 
of IS in death certificates and in Riksstroke is a cause for 
concern. In future, studies on non-dementia patients regis-
tered in Riksstroke could determine whether this is a wide-
spread issue or particular of patients with dementia.  
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OVERVIEW AND GENERAL CONCLUSIONS 
Main findings 
Management of acute ischemic stroke 
In the first part of the thesis (Paper 1), a literature review was conducted on the management 
of IS in patients with pre‐existing dementia compared to patients without dementia. We 
assessed the organizational aspects of stroke care (arrival time to the emergency department, 
access to diagnostics, access to stroke unit care), prevention of IS (OAC for patients with AF, 
antiplatelet treatment, use of statins), treatment of acute IS (IV tPA, endovascular treatment) 
and rehabilitation. 
According to current literature, there is a lack of studies that would specifically investigate the 
influence of dementia on prehospital care. Older age and comorbidity were in some studies 
associated with greater pre-hospital delay.125, 126 There is also a lack of data on acute 
neuroimaging in dementia patients with acute stroke. However, older age was associated with 
the less frequent use of neuroimaging (71% of patients < 65 years vs. 51% > 85).127 
Patients with dementia are less likely to receive thrombolysis (0.56–10%97, 128 for patients with 
dementia vs. 1–16%97, 129, 130 thrombolysis rates in the general population vs. 2–10% of patients 
over 80 years).129, 131, 132 Three observational studies have examined safety and efficacy of IV 
tPA for the treatment of acute IS in patients with dementia.128 133 134 In the two largest matched 
case–control studies, there were no significant differences in the risks of ICH and mortality 
rates between patients with and without dementia.128, 134 In the first study, the risk of 
symptomatic ICH (11% for both groups; risk ratio (RR) 1.00, CI 0.47–2.13) and mortality (27% 
vs. 28%; RR 0.96 CI 0.60–1.55) did not differ from the matched cohort, although there was a 
trend towards greater functional disability in those with dementia (mRS 3-5 in 68% vs. 56%, 
RR 1.22 CI 0.98–1.52).134  
In the second study, no significant differences in the risks of ICH (6% vs. 5%; p=0.45) or 
hospital mortality (17% vs. 15%; p=0.31) were found between patients with and without 
dementia.128 However, the extremely low rate of IV tPA administration (0.56%) among patients 
with dementia could indicate that atypically healthy candidates were treated and therefore the 
bleeding risk may have been underestimated.  
Nor were there any significant differences in the risks of ICH (3 (14%) for dementia patients 
in the third study when compared to 7 (5%) for non-dementia patients; p=0.14).133 In this study, 
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vs. 28%; RR 0.96 CI 0.60–1.55) did not differ from the matched cohort, although there was a 
trend towards greater functional disability in those with dementia (mRS 3-5 in 68% vs. 56%, 
RR 1.22 CI 0.98–1.52).134  
In the second study, no significant differences in the risks of ICH (6% vs. 5%; p=0.45) or 
hospital mortality (17% vs. 15%; p=0.31) were found between patients with and without 
dementia.128 However, the extremely low rate of IV tPA administration (0.56%) among patients 
with dementia could indicate that atypically healthy candidates were treated and therefore the 
bleeding risk may have been underestimated.  
Nor were there any significant differences in the risks of ICH (3 (14%) for dementia patients 
in the third study when compared to 7 (5%) for non-dementia patients; p=0.14).133 In this study, 
dementia was found to be an independent predictor of mortality and poor outcome after IV tPA 
or intraarterial thrombectomy (OR 3.61, CI 1.39–9.37).133 Another recent study, also performed 
with the data from Swedish dementia and stroke registries, found that younger patients with 
dementia and IS were less likely to receive IV tPA.132 However, when they compared 
previously independent patients, these differences disappeared.132 Among patients receiving 
thrombolysis, there were no differences in symptomatic ICH (7.4% vs. 7.3%) or death at 3 
months (22.0% vs 18.8%), although patients with dementia had worse accommodation and 
functional outcomes.132 
In recent studies on endovascular treatment for acute IS, dementia was not directly mentioned 
as an exclusion criteria.135, 136 However, patients with co-morbid conditions that would 
confound the neurological and functional evaluation or compromise survival were excluded.  
Regarding post acute care, patients with dementia were less likely to be admitted to a stroke 
unit (63% vs. 68%; p = 0.012)97 or to receive more invasive interventions (3% of dementia 
patients received endotracheal intubation compared to 11% in non-dementia population).128 
Carotid imaging was less frequently used in stroke patients with pre-existing dementia (65% 
vs 81%; p < 0.001).97 Interestingly, one study showed that patients with dementia were more 
likely to receive physiotherapy during hospitalisation (91 % vs. 87 %)97 and few studies found 
significant improvement in functional outcomes with rehabilitation also in patients with 
cognitive impairment.137-143 
Patients with dementia were less likely to be discharged home (19 % vs  41 %),134  and more 
likely to be disabled (64% vs. 59%).134  After adjusting for other recognized predictors of 
mortality, several authors have described an around two- to threefold increase in mortality with 
stroke in patients with pre-existing dementia compared to nondemented patients.30, 128, 144 
To conclude, patients with pre‐existing dementia are managed differently for acute IS 
compared to the general population, including organizational aspects of stroke care, prevention 
of stroke, treatment of acute IS and rehabilitation, which confirmed our first hypothesis. 
Patients with dementia were less likely to receive IV rtPA, secondary stroke prevention, 
different diagnostic procedures, more invasive interventions or be admitted on stroke units. 
However, according to the literature, there is a lack of studies that would specifically 
investigate the influence of dementia on prehospital care, endovascular treatment, and general 
supportive care in patients with dementia.  
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Stroke prevention 
The cornerstones of secondary stroke prevention are antiplatelet therapy, treatment of 
hypertension, AF, DM, hyperlipidemia, management of lifestyle risk factors and early carotid 
revascularisation in patients with ipsilateral severe carotid artery stenosis.145, 146 Concerns exist 
for an increased risk for ICH with acetylsalicylic acid (ASA) in patients with AD.65 However, 
the consensus is that the benefit of secondary prevention would supersede the increased 
bleeding risk. ASA is widely prescribed for patients with VD. In one study, almost 80% of 
patients with vascular risk factors and dementia received ASA.147 
Statins are also an important component in the secondary prevention of IS.145 According to the 
guidelines, it is recommended that for patients over 75 years the benefits and adverse effects 
are to be assessed before initiating a statin therapy, irrespective of dementia status.148 Concerns 
were raised about the harmful effect of statins on cognition,149-151 but the current evidence is 
controversial, with recent research not supporting the negative effects of statins on cognition.152 
In patients with pre-existing dementia, under-prescription for statins (64 % in dementia vs. 71 
% in controls) has also been reported. 97 
OAC for primary and secondary stroke prevention in patients with AF and dementia is also 
sometimes withheld, despite dementia not being listed as an exclusion criterion in the current 
guidelines.111, 112 The underutilization of OAC in patients with AF is a common problem, not 
only in older patients and those with dementia. In the general population, according to the 
GARFIELD (Global Anticoagulant Registry in the FIELD) international observational study, 
43% of patients with AF with low stroke risk and 62% with high risk received OAC.153 
Similarly, a large American study showed that less than half of high-risk patients with AF 
(45%) received OAC.154 A study that investigated the influence of dementia status on 
secondary stroke prevention treatment concluded that dementia is a significant independent 
factor of nontreatment with aspirin or warfarin when otherwise indicated for the prevention of 
recurrent stroke (OR = 2.57, 95% CI 1.04–6.30).113 In our second study, examining OAC with 
warfarin for primary stroke prevention in patients with dementia, we also found a relatively 
low number of patients who received warfarin treatment (26%). 
The main results of our second study (Paper 2) showed that patients on warfarin had fewer IS 
than those without treatment (5.2% versus 8.7%; p < 0.001), with no differences compared to 
antiplatelets. In adjusted analyses, warfarin was associated with a lower risk for IS (HR 0.76, 
CI 0.59–0.98), while antiplatelets were associated with an increased risk (HR 1.25, CI 1.01–
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recurrent stroke (OR = 2.57, 95% CI 1.04–6.30).113 In our second study, examining OAC with 
warfarin for primary stroke prevention in patients with dementia, we also found a relatively 
low number of patients who received warfarin treatment (26%). 
The main results of our second study (Paper 2) showed that patients on warfarin had fewer IS 
than those without treatment (5.2% versus 8.7%; p < 0.001), with no differences compared to 
antiplatelets. In adjusted analyses, warfarin was associated with a lower risk for IS (HR 0.76, 
CI 0.59–0.98), while antiplatelets were associated with an increased risk (HR 1.25, CI 1.01–
1.54) compared to no treatment. Compared to the treatment with antiplatelets, warfarin was 
associated with a lower risk for IS (HR 0.62 (0.49-0.78). These results are in line with the 
protective effect of warfarin for stroke in patients with AF observed in the general 
population.99-101, 155-159  However, there has been a lack of evidence that warfarin protects 
against IS in patients with dementia. 
The most commonly feared secondary effects of warfarin are hemorrhages. Previous studies 
on primary as well as secondary stroke prevention in patients with AF found an increase in the 
absolute risk for ICH and major bleeding.99-101, 157, 159 In our study the crude rates of ICH (1.9% 
for warfarin vs. 1.6% for antiplatelets (p=0.553) vs. 1.3% no treatment (p=0.136)) and any-
cause hemorrhage did not differ between the treatment groups. However, survival analyses 
revealed an association between an excess risk of any-cause hemorrhage and warfarin 
compared to antiplatelet treatment (HR=1.28, p=0.027). There were no significant differences 
for any-cause hemorrhage between warfarin or antiplatelets compared to no-treatment. Our 
findings suggest that the hemorrhagic risk in patients with dementia is similar to what was 
previously reported among older patients.100, 102 
When prescribing warfarin, the risk of IS must be weighed against the risk of ICH and other 
hemorrhagic complications. In our data, the absolute rate of IS during the follow-up was 
approximately 3-5 times higher than that for ICH, which is comparable to other studies. In the 
European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), which 
investigated the secondary prevention of stroke and compared OAC with a target INR between 
2.0-3.0 with aspirin treatment, the annual incidence of ICH was between 0.31%-1.21% in 
anticoagulated patients.160 The incidence of ICH in similar patients treated with aspirin was 
0.39% per year.161  
In the present study, warfarin- and antiplatelet treatment were associated with a lower risk for 
death compared to no treatment. Compared to antiplatelet treatment, there was a non-
significant trend towards a lower risk for death with warfarin. Some previous studies reported 
better survival with warfarin compared to placebo,100, 159 while in other studies comparing 
warfarin to antiplatelet therapy there were no significant differences in survival.101, 157, 158 
However, this protective effect has to be interpreted with care because there might be a bias 
that patients with a lower life expectancy were not treated at all.  
To conclude, this study (Paper 2) supports the use of warfarin in appropriate cases in patients 
with dementia. The low prevalence of patients receiving OAC in this study with relatively low 
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hemorrhagic complications indicates that further gains in stroke prevention are possible. As we 
hypothesized, OAC for AF compared to antiplatelet treatment in patients with dementia was 
associated with a lower risk of IS and lower mortality. We expected an increased risk of 
hemorrhage in patients receiving warfarin, however, there was no significant increase in 
nontraumatic ICH compared to both antiplatelet and no treatment. Regarding any-cause 
hemorrhage, we did not find any differences compared to no treatment, while compared to 
antiplatelet treatment, there was a higher risk of any-cause hemorrhage with warfarin, but the 
absolute risk was small. Our second hypothesis was therefore partially confirmed. 
 
Stroke as a cause of death in patients with dementia 
In Paper 3, we examined stroke as a cause of death in patients with dementia. There were 8% 
of patients with dementia in our study who died of IS, which is slightly more compared to the 
6% that die from IS in the general population.3 The increased risk of mortality for patients with 
dementia is probably associated with a combination of factors – an increased burden of CVD 
in patients with dementia, a tendency toward undertreatment for stroke prophylaxis, or 
noncompliance with treatment in this population. Some other studies evaluated stroke as a 
cause of death in dementia patients 34, 162-165 providing conflicting results. Some showed that 
death due to CVD was more common in dementia patients than in the general population 163 
while others did not demonstrate a difference, 164 or showed opposite results.162 Death from 
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hemorrhagic complications indicates that further gains in stroke prevention are possible. As we 
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is by definition associated with CVD and therefore patients with VD also have a higher 
prevalence of cardiovascular risk factors.166 The most common type of dementia in patients 
who died from other causes was AD. Some studies showed that patients with dementia had an 
increased risk of stroke,26 others showed that patients with AD did not have an altered risk of 
ischemic stroke compared to those without dementia, whereas patients with VD had an 
approximately 2 fold increased risk.167   
As suggested in previous studies, we hypothesized that the treatment for BPSD is associated 
with a higher risk for death from IS. However, the hypothesis was not confirmed. In our study, 
there were no differences in the use of antipsychotics, antidepressants, acetylcholinesterase 
inhibitors, memantine, anxiolytics, or hypnotics between the patients dying from IS and 
registered in Riksstroke, patients dying from IS without being registered in Riksstroke and 
those dying from other causes. The patients who died from IS took more cardiovascular 
medications. 
Contrary to our findings, previous studies found a significantly increased risk of mortality and 
higher prevalence of stroke (10% vs.7%; p ≤ 0.001) in patients who were taking anxiolytic and 
hypnotic drugs.78 Recently, concern has been raised about the increased risk of stroke with the 
use of antipsychotics, both in the general population and patients with dementia.74, 75, 77, 168 In 
some studies, the risk of death was about 1.2-1.6 times higher and the risk of cerebrovascular 
side effects was about 1.3-2.0 times higher in patients with dementia treated with antipsychotics 
compared to the no-treatment group.76, 77 Haloperidol was associated with the largest mortality 
risk of 3.8% (95% CI, 1.0–6.6; P < .01), followed by atypical antipsychotics.169 Because of the 
higher awareness of possible side effects, the use of antipsychotics has been restricted in 
patients with dementia.170 In our study, the use of antipsychotics among patients with dementia 
was low - 6.5% in patients who died from IS and were registered in Riksstroke compared to 
8.1% who died from other causes.171 
 
Death certificate diagnosis 
We additionally found that less than half of the patients (38.9%) who had IS in their death 
certificate had been registered in Riksstroke during the year prior to death. There are a few 
possible explanations for this low number of registrations in the stroke register. First, 
Riksstroke covers over > 90% of stroke events in Sweden, so around 10% of strokes may be 
missed.122 Further, some patients with strokes, which contributed to death, may have survived 
longer than one year after the stroke event and would have been excluded from this study: 
however, it may be difficult to attribute these casesof death to stroke. A secondary analysis was 
made including all patients with previous Riksstroke registration irrespective of the time 
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between stroke and death, where the number of patients with an established stroke diagnosis 
increased to 52%. In the previous studies examining mortality after IS, the highest mortality 
rate occurred in the first months after IS, but remained elevated even after several years 
compared to the general population.172-174 
This finding raises concerns about the accuracy of death certificate stroke diagnoses. Death 
certificates are meant to reflect the relevant information about the cause of death and these data 
are increasingly used to identify health priorities. Mortality data are the key for epidemiological 
research. However, the quality of death certificates varies over time and regions. There are 
different problems associated with the quality of death certificate diagnoses; from diagnostic 
difficulties to methodological differences and changes in medical terminology as well as 
diagnostic techniques over time.175-178 Particularly in older individuals it is often difficult to
attribute death to a single cause.177 With increasing age, death can be caused by multiple 
pathologies. In an epidemiological study comparing data during the twentieth century, in 1917 
only 35% of deaths had more than one cause of death, by 1955 this increased to 60% of deaths 
with multiple causes and by 1990 the number increased to more than 80%.178 
High error rates in death certification have been described - approximately 33-41% of 
incorrectly identified causes of death, with a disproportionate overrepresentation of 
cardiovascular events.179 For example, data from the Framingham Heart Study suggest that 
cardiovascular causes of death are overstated in at least 24% of cases.180 This finding is most 
pronounced in the oldest age group – a study thatexamined the accuracy of death certificates 
has shown coronary heart disease to be overestimated by 8% to 24% overall and between 43% 
and 109% for patients of 85 years and older.181 The Framingham Heart Study also found a high 
error rate for stroke – approximately 40% false negative rate in death certificates, which 
significantly increased with the increasing age at death and with increasing interval from last 
stroke to death.182  
The Swedish quality registers have a long tradition in improving quality of care and are often 
used in research. A recent study on Swedish death certificates found a high agreement of 87-
88% with clinical records for cardiovascular causes of death at the 3-digit level of the ICD-
10.183 However, another Swedish study found that the main diagnosis from the patient's final 
hospital discharge record and the underlying cause of death agreed in less than half of the 
cases.184 Another study from Sweden that analyzed stroke incidence and survival pointed to a 
possible underestimation of stroke incidence (foraround 10%) in the previous studies and 
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Methodological considerations 
The current thesis has several limitations. In the first review article, the breadth of the topic 
precluded a systematic review and the reference list may have been influenced by the selection 
bias of the authors.  
The strength of both the second and the third study is a uniquely large sample of patients with 
dementia from different health care settings, reflecting the current clinical practice in Sweden. 
The information on the causes of death, drugs and comorbidities was derived from nationwide 
health registers that have complete coverage in the country. However, there are some 
limitations in the data obtained from registries. There may be a selection bias in the studies 
based on the Swedish quality registers which, contrary to those mentioned above, do not have 
a complete coverage in the country. Riksstroke has a high national coverage of IS events 
(>90%).123 SveDem included 52% of memory clinics and 48% of primary care units in Sweden 
during the time of this study, which may differ from non-registered patients.  
The validity of the clinical diagnoses is a concern. However, quality control of the data in 
SveDem is performed by random cross-checks of histories and entries114 and less than 5% of 
dementia diagnoses change during the first year of follow-up. The diagnosis of AF, and 
comorbidities was obtained from the Swedish National Patient register,117 which has a high 
overall validity of diagnoses (about 85-95%) with very high positive predictive values for a 
stroke/transient ischemic attack (98.6%).117  
In the second study, residual confounding factors may be present. In particular, information 
about important factors affecting treatment decisions, such as possible contraindications for 
warfarin treatment, patient's preferences, compliance and INR were not available. Patients were 
classified by their treatment status at the time of dementia diagnosis; however, it is possible 
that patients changed treatment in the course of follow-up. These changes in the treatment 
status could lead to an underestimation of the protective effect of warfarin on stroke risk, but 
also to an underestimation of the hemorrhagic complications. Unfortunately, patients with 
NOAC were not included in this study due to these treatments being infrequent during the 
observed time of the study.  
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Regarding the second and particularly the third study, we did not have the neuropathologic 
validation of the dementia subtype and stroke diagnosis in our patients. In both studies, another 
limitation was unavailable information on patients' cognition and stage of dementia at the time 
of stroke and death because of the SveDem records data on MMSE at the time of diagnosis. 
The weakness of both studies is also the absence of cognitively normal controls.  
 
Future perspectives  
The care of patients with dementia raises medical, organisational and ethical issues. Providing 
high-quality care in old age includes adhering to the basic principles of medical ethics, 
including autonomy, beneficence, non-malfeasance and justice.186 Applying these principles to 
the patients with dementia undergoing IS brings out the limitations of the healthcare system, 
our evidence base, and physician’s values and beliefs which alongside medical knowledge 
influence decision making.187 While patients with dementia deserve to be treated with the best 
medical care, this care may not always mean increased intervention.64 In the final stages, 
dementia can be considered a palliative diagnosis and then it may not be justifiable to 
administer aggressive and costly treatments such as IV tPA.187 This contrasts with the 
experience of patients in earlier disease stages where withholding treatment is not appropriate.  
Further research is needed to fully establish and adapt therapeutic protocols for patients with 
dementia. As pointed in the last AHA/ASA review on the criteria for IV rtPA use, alteplase 
treatment of patients with pre-existing dementia with acute IS is a high-priority research area.83 
We agree with the opinion, that age alone should not be an exclusion criterion, nor, for example, 
a mild pre-existing dementia. But not all dementia patients are candidates for all interventions, 
so it is crucial to target the right populations. Further research would need to find models to 
predict the risks and benefits of treatment with IV rtPA or OAC in dementia patients, focusing 
on different patient subgroups, according to different dementia diagnoses, and varying levels 
of cognition and functioning.  
At present, it would be technically and ethically difficult to conduct placebo-controlled trials 
on thrombolysis in patients with dementia and similarly with other treatments, such as OAC 
for the treatment of AF or hospitalization in stroke units, which are established for other patient 
groups. Epidemiological studies on large clinical cohorts could be an important first step in 
determining which interventions are associated with better outcomes for patients with different 
types of dementia and at different disease stages. 
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of cognition and functioning.  
At present, it would be technically and ethically difficult to conduct placebo-controlled trials 
on thrombolysis in patients with dementia and similarly with other treatments, such as OAC 
for the treatment of AF or hospitalization in stroke units, which are established for other patient 
groups. Epidemiological studies on large clinical cohorts could be an important first step in 
determining which interventions are associated with better outcomes for patients with different 
types of dementia and at different disease stages. 
With this work we hope to contribute to better understanding of the management and 
prevention of IS in patients with pre‐existing dementia and open the ground for further 
research. There are still knowledge gaps in different aspects of stroke management in patients 
with dementia that need to be evaluated, for example on prehospital care, endovascular 
treatment, general supportive care, and the impact of secondary stroke prevention in patients 
with dementia. Our study showed that use of warfarin was associated with a lower risk of IS 
and lower mortality in Swedish patients with dementia without excess hemorrhagic 
complications. However, in the future studies it would be of interest to include more data on 
some important factors that could affect the results, particularly possible contraindications for 
warfarin treatment, compliance, INR at the time of occurrence of the adverse events, time in 
therapeutic range. With the increasing use of NOACs, there is a need to assess the risks and 
benefits of NOACs in patients with AF and dementia and compare them to the treatment with 
warfarin. Additionally, the thesis also questions the accuracy of death certificate stroke 
diagnoses. Future research on death certificates that will include neuropathologic validation of 
the dementia subtype and stroke diagnosis can more reliably determine the quality of death 
certificates.   
This study was conducted with the data merged from different Swedish health registries. 
Sweden was one of the first countries in the world to start using quality health registries. There 
are around 100 different quality registries in Sweden today.188 SveDem, a quality database for 
patients with different dementia disorders, was established in May 2007 with the main aim of 
monitoring and improving the quality of diagnostic work-up, treatment and care of dementia 
patients in Sweden.114 Registries have a longer tradition in other fields of medicine but are 
relatively new in dementia.189 As SveDem has demonstrated, dementia registries facilitate 
better diagnosis, management, and care of patients with dementia and can consequently 
significantly contribute to reduced costs of dementia and improve the standards of diagnosis 
and care.114 In practice, more than half of the registries in existence are aimed at research, while 
other dementia registries collect epidemiological or quality care data.189 There is a need to 
create a similar quality database for patients suffering from different dementia disorders and 
stroke in Slovenia.  
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RAZŠIRJENI POVZETEK 
Uvod 
Z daljšanjem življenjske dobe narašča prevalenca možgansko-žilnih bolezni in demence.3 
Možganska kap in demenca sta povezani na več načinov. Možganska kap je lahko glavni vzrok 
demence in se jo uvršča v t. i. vaskularno demenco190, lahko pa tudi pospeši razvoj 
Alzheimerjeve demence (AD).37 Po drugi strani imajo bolniki s kognitivnim upadom višje 
tveganje za možgansko kap.39, 40 Za to obstaja več možnih razlag. Srčno-žilni dejavniki, kot so 
arterijska hipertenzija, hiperlipidemija in sladkorna bolezen, so dejavniki tveganja tako za 
ishemično možgansko kap (IMK) kot za razvoj demence.39, 44 Srčno-žilne bolezni so pogoste 
pri bolnikih z demenco in kar 70 % teh bolnikov prejema zdravila za zdravljenje srčno-žilnih 
bolezni.68, 69 Tudi zdravila za zdravljenje demence in vedenjskih motenj pri demenci lahko 
vplivajo na tveganje za IMK: antipsihotiki lahko povečajo tveganje za IMK,73 zdravljenje z 
inhibitorji acetilholinesteraze pa naj bi zmanjšalo tveganje za miokardni infarkt in IMK.191 
Komplianca pri jemanju zdravil pri bolnikih z demenco je vprašljiva in lahko vodi do višjega 
tveganja za IMK.66, 67  
Ena od možnih razlag je, da kognitivni upad odraža »tihe« možganske kapi in bolezen drobnih 
žil v možganih (cerebral small vessel disease – CSVD), kar je povezano z višjim tveganjem za 
razvoj kapi.42, 44 CSVD je pogosto povezana z žilnimi dejavniki tveganja, s starostjo in s 
cerebralno amiloidno angiopatijo (CAA).12 Pri CAA pride do odlaganja amiloida v stenah 
arterij. CAA je pogosteje opisana pri bolnikih s kognitivnim upadom kot v splošni populaciji.50 
Na obdukcijah je bila CAA prisotna pri do 98 % bolnikov z AD ter pri 10 % starejših od 60 let 
in 50 % starejših od 90 let.55, 56 Posledice CSVD se lahko kažejo kot lakunarne možganske 
kapi, levkoaraioza, znotrajmožganske krvavitve (ZMK) ali možganske mikrokrvavitve 
(cerebral microbleeds – CMB).50 Ugotovljeno je bilo, da je levkoaraioza povezana s 
pomembno okvaro endotelijske funkcije, ki presega pričakovano, povezano zgolj z dejavniki 
tveganja za možgansko-žilne bolezni, in kaže na možno primarno intrinzično endotelijsko 
disfunkcijo pri bolnikih z levkoaraiozo.192 Prisotnost CMB in levkoaraioze je lahko povezana 
z višjim tveganjem za krvavitev pri trombolitičnem60, 61 in antikoagulantnem zdravljenju 
(AKZ).62, 63  
Pri bolnikih z znano demenco je pogostost zdravljenja z intravensko trombolizo z 
rekombinantnim tkivnim aktivatorjem (IV tPA) med 0.56 % in 10 %.97, 128 Raziskav na tem 
področju je malo in so si nasprotujoče. V zadnjem pregledu kriterijev za zdravljenje z IV tPA 
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American Heart Association / American Stroke Association (AHA/ASA) so mnenja, da je za 
bolnike z znano demenco  zdravljenje z IV tPA lahko koristno, vendar je potrebno upoštevati 
pričakovano življenjsko dobo in izhodiščno stopnjo funkcioniranja.83 
Podobno kot IV tPA je tudi AKZ za sekundarno preventivo možganske kapi pri bolnikih z 
atrijsko fibrilacijo (AF) redkeje predpisano pri bolnikih z demenco.113 V smernicah American 
Academy of Neurology (AAN) so sicer mnenja, da je zaenkrat na voljo premalo podatkov za 
odločitev glede učinkovitosti in varnosti AKZ za zdravljenje AF pri bolnikih z zmerno ali 
napredovalo demenco.112 Smernice European Stroke Organisation (ESO) demence specifično 
ne navedejo kot izključitveni kriterij, vendar ne priporočajo AKZ pri bolnikih s prisotnostjo 
pogostih padcev ali slabo adherenco.82 Podobno tudi smernice European Society of Cardiology 
(ESC) ne navedejo demence kot izključitveni kriterij, razen v primeru slabe kompliance.111  
 
Cilji  
1. Preučiti literaturo, ali so bolniki z demenco, ki so zboleli z IMK, obravnavani drugače kot 
bolniki brez demence. 
2. Preučiti tveganje in učinkovitost AKZ z varfarinom za zdravljenje AF pri bolnikih z 
demenco, jo primerjati z bolniki, ki prejemajo antiagregacijsko terapijo in tistimi brez 
antikoagulantne ali antiagregacijske terapije.  
3. Preučiti klinične značilnosti bolnikov z demenco, ki so umrli zaradi možganske kapi in jih 
primerjati z bolniki, ki so umrli zaradi drugih vzrokov.  
 
Hipoteze 
1. Bolniki z demenco so pri IMK v primerjavi s splošno populacijo obravnavani drugače tako 
v organizacijskem smislu (hitrost prihoda v urgentno ambulanto, dostopnost do preiskav, 
sprejem na enoto za možgansko kap), preventivi IMK (AKZ pri bolnikih z AF, antiagregacijsko 
zdravljenje, uporaba statinov), zdravljenju akutne IMK (z IV tPA, endovaskularnim 
zdravljenjem) in rehabilitaciji. 
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2. Zdravljenje AF z AKZ je v primerjavi z antiagregacijskim zdravljenjem pri bolnikih z 
demenco povezano z manj IMK in manjšo smrtnostjo, vendar z večjo možnostjo zapletov s 
krvavitvijo, ki pa je sorazmerno majhno glede na korist preventive IMK. 
3. Bolniki, ki so v zgodnji fazi demence (KPSS > 20) zdravljeni zaradi vedenjskih in psihičnih 
simptomov ob demenci, imajo večjo verjetnost za smrt zaradi možganske kapi.  
 
Metode 
Raziskava je sestavljena iz treh delov.  
 
1. del 
V prvem delu je bil namen zbrati obstoječe podatke iz literature o obravnavi akutne IMK pri 
bolnikih z znano demenco in jih primerjati s splošno populacijo. Pregled obravnave IMK je 
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2. del  
Druga raziskava je longitudinalna kohortna študija, ki temelji na podatkih o bolnikih iz 
Švedskega nacionalnega registra za demence (Swedish Dementia Registry - SveDem).114 
Podatki o sočasnih boleznih in zdravljenju so bili pridobljeni iz nacionalnega švedskega 
registra bolnikov (Swedish National Patient Register)117 in nacionalnega švedskega registra 
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preizkusa spoznavnih sposobnosti (KPSS), bivalne razmere ob nastopu demence in uporaba 
zdravil (inhibitorjev acetilholinesteraze, NMDA antagonistov, zdravil za srčno-žilne bolezni, 
antidepresivov, anksiolitikov in hipnotikov). V SveDem so vključene naslednje diagnoze 
demence: AD, vaskularna demenca (VD), mešana AD in VD (MD), demenca z Lewyjevimi 
telesci (DLT), frontotemporalna demenca (FTD), demenca pri Parkinsonovi bolezni (PDD) in 
neopredeljena demenca (ND). 
Podatki o uporabi zdravil so bili pridobljeni iz nacionalnega švedskega registra zdravil 
(Swedish Prescribed Drug Register) za obdobje 2005–2014. Zdravila so bila kodirana glede na 
Anatomical Therapeutic Chemical classification system. Podatki o sočasnih boleznih iz 
Swedish National Patient Register so bili na voljo iz obdobja od leta 2000 do konca 2014. 
Register pokriva tako hospitalno kot ambulantno obravnavo bolnikov na Švedskem in ima 
visoko veljavnost diagnoz (85–95 %).117 Bolezni so kodirane v skladu z Mednarodno 
klasifikacijo bolezni 10 (ICD-10).  
Med bolnike z AF so bili uvrščeni tisti bolniki, ki so prejeli diagnozo AF (I48) od leta 2000 do 
časa diagnoze demence. Iz tega obdobja smo pridobili tudi podatke o ostalih boleznih, ki so v 
raziskavo uvrščene kot »sočasne bolezni«. Za komorbidnosti smo predpostavili, da glede na 
to, da smo spremljali kronične bolezni, veljajo tiste, ki so bile diagnosticirane v času do 
postavitve diagnoze demence.  
Za izid zdravljenja smo upoštevali sledeče diagnoze, ki so se pojavile po diagnozi demence: 
IMK (I63), netravmatska ZMK (I60–I62), krvavitev in smrt. Spremenljivka »krvavitev« je 
vključevala diagnoze: travmatska ZMK (S063–S068); netravmatska ZMK (I60–I62); krvavitev 
iz dihal (R04); anemija (D50 in D62); neopredeljena krvavitev (R58); krvavitev iz prebavil 
(K92); in travmatski šok (T794).  
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3. del 
Tudi tretja študija temelji na podatkih o bolnikih, ki so bili v obdobju 2007–2012 vpisani v  
Švedski nacionalni register za demence (Swedish Dementia Registry - SveDem).114 Podatki o 
sočasnih boleznih in zdravljenju so bili pridobljeni iz nacionalnega švedskega registra bolnikov 
(Swedish National Patient Register)117 in nacionalnega švedskega registra zdravil (Swedish 
Prescribed Drug Register).119  
Podatki o možganski kapi so bili pridobljeni iz švedskega nacionalnega registra za možganske 
kapi (Swedish Stroke Registry - Riksstroke).123 V študijo so bili vključeni bolniki z IMK v 
obdobju 2007 –2014. Podatki o smrti iz nacionalnega švedskega registra prebivalstva (Swedish 
Population Register). IMK je bila smatrana za vzrok smrti, če je bila na mrliškem listu 
omenjena kot glavni ali posredni vzrok smrti (ICD-10 koda I63). Vsi drugi vzroki smrti pri 
bolnikih so bili vključeni pod spremenljivko »bolniki umrli zaradi drugih vzrokov«.  
Bolnike, ki so umrli do konca leta 2014, smo razdelili v 3 poskupine: (1) bolniki, ki so umrli 
zaradi IMK in so bili v zadnjem letu pred smrtjo vpisani v švedski nacionalni register za 
možganske kapi (Riksstroke); (2) bolniki, ki so umrli zaradi IMK in niso bili vpisani v 
Riksstroke ter (3) bolniki, ki so umrli zaradi drugih vzrokov. 
Primerjali smo osnovne značilnosti opisanih skupin bolnikov v času diagnoze demence 
(starost, spol, rezultat KPSS-ja, bivalne razmere), uporabo zdravil (inhibitorjev 
acetilholinesteraze, NMDA antagonistov, zdravil za srčno-žilne bolezni, antidepresivov, 
anksiolitikov in hipnotikov) in vrsto demence (AD, VD, MD, DLT, FTD, PDD in ND).  
 
Statistične metode 
V drugi študiji smo bolnike razdelili v tri podskupine: (1) bolniki z AKZ, (2) bolniki z 
antiagregacijsko terapijo in (3) bolniki brez antikoagulantne in antiagregacijske terapije ter 
njihove osnovne značilnosti v času diagnoze demence in izide med seboj primerjali z uporabo 
hi-kvadratnega testa oz. Studentovega t-testa.  
Analiza preživetja za določitev dejavnikov povezanih s tveganjem za IMK, ZMK, krvavitev in 
smrt je bila izvedena z uporabo Coxovega regresijskega modela za oceno razmerij ogroženosti 
(hazard ratios, HR) s 95 % intervalom zaupanja (confidence intervals, CI). Končni modeli so 
bili pridobljeni na podlagi testiranja vseh spremenljivk, ki so bile pri univariatni primerjavi 
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Statistične metode 
V drugi študiji smo bolnike razdelili v tri podskupine: (1) bolniki z AKZ, (2) bolniki z 
antiagregacijsko terapijo in (3) bolniki brez antikoagulantne in antiagregacijske terapije ter 
njihove osnovne značilnosti v času diagnoze demence in izide med seboj primerjali z uporabo 
hi-kvadratnega testa oz. Studentovega t-testa.  
Analiza preživetja za določitev dejavnikov povezanih s tveganjem za IMK, ZMK, krvavitev in 
smrt je bila izvedena z uporabo Coxovega regresijskega modela za oceno razmerij ogroženosti 
(hazard ratios, HR) s 95 % intervalom zaupanja (confidence intervals, CI). Končni modeli so 
bili pridobljeni na podlagi testiranja vseh spremenljivk, ki so bile pri univariatni primerjavi 
različne med skupinama (p<0,25) in za katere je iz literature znano, da vplivajo na umrljivost 
pri bolnikih z demenco. Končni modeli so bili prilagojeni za starost, spol, število zdravil, 
KPSS, tip demence, bivanje v inštitucijah, predhodno sladkorno bolezen, povišan krvni tlak, 
srčno popuščanje, preteklo IMK, preteklo krvavitev, jetrne in ledvične bolezni. Modeli so bili 
ponovljeni za vse 4 izide: IMK, netravmatska ZMK, krvavitev in smrt. Posebej so bili 
ponovljeni modeli s stratifikacijo po spolu, prisotnosti srčnega spodbujevalnika, predhodni 
IMK in predhodni krvavitvi.  
V tretji študiji smo z uporabo hi-kvadratnega testa oz. Studentovega t-testa primerjali 
značilnosti bolnikov z demenco, ki so umrli zaradi IMK in bili vpisani v Riksstroke, bolnikov, 
ki so umrli zaradi IMK in niso bili vpisani v Riksstroke ter bolnikov, ki so umrli zaradi drugih 
vzrokov.  
Analize so bile izvedene v programu Statistical Package for the Social Sciences software 
version 22 (IBM Corporation, Armonk, NY, USA) in STATA® version 12.1 (StataCorp, 
College Station, TX, USA). 
 
Etični vidik 
2. in 3. študija sta bili izvedeni v skladu s Helsinško deklaracijo in odobreni pri lokalni etični 
komisiji v Stockholmu. Vsak bolnik je bil seznanjen z vpisom v register in je imel možnost 
zavrniti sodelovanje. Podatki so bili pred analizo anonimizirani. 
 
Rezultati 
1. del 
V prvem delu smo zbrali obstoječe podatke iz literature o različnih vidikih obravnave akutne 
IMK pri bolnikih z znano demenco. Pri bolnikih z znano demenco je bila uporaba IV tPA za 
zdravljenje IMK manj pogosta kot pri bolnikih brez demence (0.56–10 % pri bolnikih demenco 
vs. 1–16 % v splošni populaciji vs. 2–10 % pri bolnikih > 80 let).97, 131 Raziskav, ki bi 
preučevale varnost in učinkovitost zdravljenja IMK z IV tPA pri bolnikih z demenco, je malo 
in imajo nasprotujoče si rezultate.128, 133, 134 V dveh večjih niso ugotovili pomembnih razlik v 
tveganju za ZMK in umrljivost pri bolnikih z in brez demence,128, 134 prav tako ni bilo 
90
statistično pomembnih razlik v tveganju za ZMK v manjši študiji, vendar je bila ugotovljena 
višja umrljivost pri bolnikih z demenco.133  
V zadnjih letih je z razvojem endovaskularnega zdravljenja prišlo do pomembnega izboljšanja 
izidov zdravljenja akutne IMK.135, 136 V teh študijah demenca sicer ni bila neposredno 
omenjena kot izključitveni kriterij, vendar so bili izključeni bolniki s sočasnimi boleznimi, ki 
bi lahko vplivale na nevrološki izid.  
Sekundarna preventiva možganske kapi v splošnem temelji na antiagregacijski terapiji, 
zdravljenju arterijske hipertenzije, sladkorne bolezni, hiperlipidemije, AF in zgodnji karotidni 
revaskularizaciji pri bolnikih s pomembno karotidno stenozo.145 Kjub temu da so raziskave 
nakazale višje tveganje za ZMK pri bolnikih z AD na antiagregacijski terapiji,65 je v splošnem 
sprejeto, da korist sekundarne preventive IMK pretehta nad možnostjo višjega tveganja za 
krvavitve. Antiagregacijska terapija z aspirinom je pogosto predpisana pri bolnikih z 
vaskularno demenco, in sicer naj bi jo prejemalo skoraj 80 % bolnikov z žilnimi dejavniki 
tveganja in demenco.147  
Uporaba statinov je pomembna komponenta sekundarne preventive IMK.145 Za bolnike, 
starejše od 75 let, ne glede na prisotnost demence, smernice priporočajo individualno presojo 
koristi in stranskih učinkov pred uvedbo terapije148. Prisotnost demence je povezana z manjšo 
uporabo statinov (64 % pri bolnikih z demenco vs. 71 % v kontrolni skupini).97 Podatkov o 
vplivu uporabe statinov na sekundarno preventivo pri bolnikih z demenco zaenkrat ni. Tudi 
AKZ za sekundarno preventivo možganske kapi je pri bolnikih z AF redkeje predpisana kot 
pri bolnikih z demenco.113  
Potrebno je opozoriti tudi na organizacijski vidik obravnave IMK. Študij, ki bi preučevale vpliv 
demence na prehospitalno obravnavo kapi, zaenkrat ni, vendar je znano, da višja starost in 
komorbidnosti prispevajo k daljšemu času prihoda v bolnico.126 Pomembna pridobitev v 
obravnavi IMK so enote za možgansko kap, za katere je bilo dokazano, da izboljšajo prognozo 
ne glede na spol, starost, tip kapi.82 Bolniki z demenco so imeli nekoliko manjšo verjetnost za 
sprejem na enoto za možgansko kap (63 % vs. 68 % pri bolnikih brez demence; p=0,012).97 
Pri bolnikih z demenco so bili redkeje opravljeni bolj invazivni posegi.128 Glede uporabe 
slikovne diagnostike pri IMK pri bolnikih z demenco ni podatkov. Višja starost je bila 
povezana z manj pogosto uporabo slikovne diagnostike (71 % bolnikov < 65 let vs. 51 % > 
85).127 Ultrazvok vratnih žil je bil redkeje opravljen pri bolnikih z znano demenco. 97  
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Pri bolnikih z demenco je manjša verjetnost odpusta v domačo oskrbo (19 vs. 41 % pri bolnikih 
brez demence) in večja verjetnost invalidnosti (64 vs. 59 %).134 Bolniki z demenco so bili v eni 
študiji bolj pogosto deležni fizioterapije tekom hospitalizacije v primerjavi z bolniki brez 
demence (91 % vs. 87 %).97 Rezultati nekaterih študij kažejo na pomembno izboljšanje 
funkcionalnega stanja po rehabilitaciji tudi pri bolnikih s kognitivnim upadom.137-143 
 
2. del 
Med 49.792 bolniki, ki so bili v obdobju 2007–2014 vpisani v Švedski nacionalni register za 
demence, jih je 8.096 (16 %) imelo znano AF. Med njimi jih je bilo 21 % z AD, 30 % z VD ter 
24 % z MD. Z varfarinom je bilo zdravljenih 2.143 (26 %) bolnikov, 2.975 (37 %) jih je 
prejemalo antiagregacijsko zdravljenje in 2.978 (37 %) ni prejemalo antitrombotičnega 
zdravljenja v času diagnoze demence.  
Bolniki z AF, zdravljeni z varfarinom, so imeli manj IMK po diagnozi demence v primerjavi z 
bolniki brez te terapije (5,2 % vs. 8,7 %; p<0,001, povprečen čas sledenja 636 dni), medtem 
ko pri bolnikih z antiagregacijsko terapijo in bolnikih brez antitrombotične terapije ni bilo 
statistično pomembnih razlik.  Terapija z varfarinom je bila povezana z manjšim tveganjem za 
IMK (HR=0,76, p=0,037), medtem ko je bila antiagregacijska terapija povezana z višjim 
tveganjem za IMK (HR 1,25, p=0,037) v primerjavi z bolniki brez terapije.  
Pogostost ZMK (1,9 % pri bolnikih z varfarinom vs. 1,6 % z antiagregacijsko terapijo 
(p=0,553) vs. 1,3 % bolniki brez terapije (p=0,136)) in pogostost večjih krvavitev se ni bistveno 
razlikovala med preučevanimi skupinami. V analizi preživetja pri dementnih bolnikih, 
zdravljenih z varfarinom, ni bilo statistično pomembnih razlik glede tveganja za ZMK v 
primerjavi z dementnimi bolniki z antiagregacijsko terapijo in bolniki brez antitrombotičnega 
zdravljenja. Pri bolnikih z varfarinom je bilo višje tveganje za krvavitev v primerjavi z bolniki 
z antiagregacijsko terapijo (HR=1,28, p=0,027). Zdravljenje z varfarinom in z antiagregacijsko 
terapijo je bilo povezano z manjšo umrljivostjo v primerjavi z bolniki brez terapije.  
 
3.del 
Med 49.823 bolniki, ki so prejeli diagnozo demence v obdobju 2007–2014 na primarni ravni 
ali specialističnih klinikah, jih je 14.170 (28,4 %) umrlo do leta 2014. Med njimi jih je 1.180 
92
(8,3 %) imelo IMK za naveden vzrok smrti na mrliškem listu. Od teh jih je bilo le 459 (38,9 
%) predhodno vpisanih v Švedski nacionalni register za možganske kapi (Riksstroke).  
Pri bolnikih, ki so umrli zaradi IMK, je bila najpogostejša vrsta demenca VD, medtem ko so 
bili bolniki, ki so umrli zaradi drugih vzrokov smrti, najpogosteje diagnosticirani z AD. 
Bolniki, ki so umrli zaradi IMK in so bili vpisani v Riksstroke, so imeli višje vrednosti na  
KPSS-ju v času diagnoze demence v primerjavi z bolniki v drugih skupinah. Bolniki, ki so 
umrli zaradi IMK, so prejemali več zdravil za srčnožilne bolezni. Glede uporabe 
antipsihotikov, antidepresivov, inhibitorjev acetilholinesteraze, memantina, anksiolitikov in 
hipnotikov, se bolniki, ki so umrli zaradi IMK, niso statistično pomembno razlikovali od 
bolnikov, ki so umrli zaradi drugih vzrokov smrti.  
 
Zaključki 
Zdravljenje IMK pri bolnikih z demenco sproža številna strokovna, organizacijska in etična 
vprašanja. Bolniki z demenco so ob akutni IMK obravnavani drugače kot bolniki brez 
demence. Glede na literaturo so ti bolniki redkeje zdravljeni z IV tPA kot bolniki brez demence. 
V raziskavah, ki so preučevale varnost in učinkovitost zdravljenja IMK z IV tPA pri bolnikih 
z demenco, ni bilo razlik v tveganju za ZMK pri bolnikih z in brez demence. V dveh študijah 
ni bilo statistično pomembnih razlik v umrljivosti, pri eni pa je bila pri bolnikih z demenco 
ugotovljena pomembno višja umrljivost. Sekundarna preventiva IMK (uporaba statinov, 
antiagregacijskega zdravljenja, AKZ pri bolnikih z AF, antihipertenzivne terapije), je pri 
bolnikih z demenco redkeje predpisana. Kljub trendu staranja prebivalstva in naraščajoče 
prevalence demence, so bili bolniki z demenco do sedaj pogosto izključeni iz raziskav, ki so 
preučevale varnost in učinkovitost zdravljenja možganske kapi. Še vedno so vrzeli znanja na 
različnih področjih obravnave IMK pri bolnikih z demenco, recimo glede prehospitalne 
obravnave, endovaskularnega zdravljenja, splošnega podpornega zdravljenja, vpliva različnih 
zdravil na sekundarno preventivo pri bolnikih z demenco. Potrebne so nadaljnje raziskave za 
natančnejšo oceno koristi in tveganj zdravljenja pri teh bolnikih glede na predhodno stopnjo 
demence.  
Rezultati druge študije so potrdili hipotezo, da je AKZ z varfarinom za zdravljenje AF pri 
bolnikih z demenco povezano z manjšim tveganjem za IMK in z manjšo umrljivostjo v 
primerjavi z bolniki brez te terapije. V hipotezi smo pričakovali povečanje tveganja za 
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ugotovljena pomembno višja umrljivost. Sekundarna preventiva IMK (uporaba statinov, 
antiagregacijskega zdravljenja, AKZ pri bolnikih z AF, antihipertenzivne terapije), je pri 
bolnikih z demenco redkeje predpisana. Kljub trendu staranja prebivalstva in naraščajoče 
prevalence demence, so bili bolniki z demenco do sedaj pogosto izključeni iz raziskav, ki so 
preučevale varnost in učinkovitost zdravljenja možganske kapi. Še vedno so vrzeli znanja na 
različnih področjih obravnave IMK pri bolnikih z demenco, recimo glede prehospitalne 
obravnave, endovaskularnega zdravljenja, splošnega podpornega zdravljenja, vpliva različnih 
zdravil na sekundarno preventivo pri bolnikih z demenco. Potrebne so nadaljnje raziskave za 
natančnejšo oceno koristi in tveganj zdravljenja pri teh bolnikih glede na predhodno stopnjo 
demence.  
Rezultati druge študije so potrdili hipotezo, da je AKZ z varfarinom za zdravljenje AF pri 
bolnikih z demenco povezano z manjšim tveganjem za IMK in z manjšo umrljivostjo v 
primerjavi z bolniki brez te terapije. V hipotezi smo pričakovali povečanje tveganja za 
krvavitev pri zdravljenju z varfarinom pri bolnikih z demenco v primerjavi z antiagregacijsko 
terapijo, vendar se pogostost ZMK ni bistveno razlikovala med preučevanimi skupinami. 
Analiza preživetja pa je pokazala višje tveganje za večje krvavitve pri bolnikih z varfarinom v 
primerjavi z bolniki z antiagregacijsko terapijo, vendar brez statistično pomembnih razlik pri 
bolnikih, zdravljenih z varfarinom in z antiagregacijsko terapijo v primerjavi z bolniki brez 
antitrombotičnega zdravljenja. Druga hipoteza je bila tako delno potrjena. Rezultati te 
raziskave podpirajo uporabo varfarina pri izbranih bolnikih z demenco inbodo lahko v klinični 
praksi pripomogli k olajšanju odločitve za predpisovanje AKZ za zdravljenje AF pri preventivi 
IMK. Nizek odstotek bolnikov na AKZ kaže na možnosti izboljšave pri preventivi IMK. Glede 
na porast uporabe NOAK v zadnjih letih, je v prihodnjih študijah potrebno oceniti varnost in 
učinkovitost le-teh pri bolnikih z demenco. 
V tretji študiji se bolniki, ki so umrli zaradi IMK, in bolniki, ki so umrli zaradi drugih vzrokov, 
med seboj niso razlikovali glede prejemanja antipsihotikov, antidepresivov, inhibitorjev 
acetilholinesteraze, NMDA antagonistov, anksiolitikov in hipnotikov. To je v nasprotju z 
rezultati preteklih študij, ki so pokazale, da imajo bolniki, ki so prejemali antipsihotike, 
anksiolitike in hipnotike, višjo umrljivost in višjo prevalenco IMK kot bolniki brez terapije. 
Hipoteza, da imajo bolniki, zdravljeni zaradi vedenjskih in psihičnih simptomov ob demenci, 
večjo verjetnost za smrt zaradi možganske kapi, tako ni bila potrjena. Več kot polovica 
bolnikov, pri katerih je bil vzrok smrti, zabeležen na mrliškem listu, IMK, ni bila vpisanih v 
švedski nacionalni register za možganske kapi, kar sproža vprašanje o točnosti diagnoz 
možganske kapi na mrliških listih. Podatki o umrljivosti so pomemben del epidemioloških 
raziskav pri spremljanju trendov bolezni, kot posledično pri načrtovanju zdravstvenih ukrepov. 
Ta raziskava kaže, da so potrebne nadaljne raziskave z nevropatološko potrditvijo kliničnih 
diagnoz demence in možganske kapi, s katerimi bi lahko bolj verodostojno ocenili kakovost 
diagnoz na mrliških listih.  
Prednost te študije je velik vzorec bolnikov z demenco iz različnih okolij, ki odraža trenutno 
klinično prakso na Švedskem. Podatki o smrti, zdravilih in komorbidnostih so bili pridobljeni 
iz nacionalnih registrov, ki imajo popolno pokritost v državi; register za možganske kapi pa 
ima več kot 90 % pokritost. Uporaba registrov ima dolgo tradicijo na različnih področjih 
medicine, vendar je relativno nova na področju demenc. Kot je vidno na primeru Švedskega 
nacionalnega registra za demence, so registri lahko kazalnik kakovosti obravnave bolnikov z 
demenco in pripomorejo k boljši diagnostiki in zdravljenju bolnikov z demenco. Tudi v 
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